

EBCC-12 Scientific programme

Wednesday 18 March 2020

Opening Ceremony: Opening of the 12th European Breast Cancer Conference

10:00 - 11:00

Picasso


- 10:00 **Welcome**
Chair: Nadia Harbeck (Germany)
- 10:05 **Introduction of the European Breast Cancer Arts and Humanities Award**
Co-Chair: Tanja Spanic (Slovenia)
- 10:10 **Arts and Humanities Award - Daily Living Although-Animation**
Awardee: Sari Neyman (Finland)
- 10:20 **Introduction of the European Breast Cancer Science Award - Emmanuel van der Schueren Lecture**
Chair: Nadia Harbeck (Germany)
- 10:25 **Research and education in oncology: Two sides of the same coin**
Awardee: Fátima Cardoso (Portugal)

Clinical Science Symposium: The Axilla: How to Reduce Overtreatment

11:15 - 12:45

Picasso

- Chair: Isabel T. Rubio (Spain)
Chair: Emiel J. T. Rutgers (Netherlands)
- 11:15 **Radiation oncology**
Speaker: Elzbieta Senkus-Konefka (Poland)
- 11:30 **Imaging**
Speaker: Ruud Pijnappel (Netherlands)
- 11:45 **Surgeon in the context of pre-operative systemic therapy**
Speaker: Isabel T. Rubio (Spain)
1. *Understand surgical management of the axilla after neoadjuvant treatment*
2. *Discuss techniques to accurately assess the axilla after neoadjuvant treatments*
3. *Update de-escalation in surgical treatments in the axilla.*
- 12:00 **Surgeon in the context of upfront surgery**
Speaker: V. Galimberti (Italy)
- 12:15 **Omitting completion axillary lymph node dissection in sentinel lymph node-positive breast cancer: first results from the swedish prospective SENOMIC trial and an external validity analysis of the ongoing SENOMAC trial**
Oral Abstract SP: Jana De Boniface (Sweden)
- The generalisability of randomised clinical trials: An interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer** 1A
Jana De Boniface (Sweden)
- Omitting completion axillary lymph node dissection after sentinel node micrometastases in breast cancer - first results from the Swedish prospective SENOMIC trial** 1B
Yvette Andersson (Sweden)



- 12:30 **Tailored axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer patients is safe: 3-year follow-up of the MARI protocol** 2
 Oral Abstract SP: Marie Jeanne Vrancken - Peeters (Netherlands)

Clinical Science Symposium: Metastatic Breast Cancer


11:15 - 12:45 Dali

- Chair: Fátima Cardoso (Portugal)
 Chair: Karen Benn (Italy)
- 11:15 **Local regional treatment of metastases**
 Speaker: Jens Ricke (Germany)
- 11:30 **Management of triple -ve**
 Speaker: Giuseppe Curigliano (Italy)
- 11:45 **Management of HER2 +ve**
 Speaker: Nadia Harbeck (Germany)
- 12:00 **Management of luminal breast cancer**
 Speaker: Alessandra Gennari (Italy)
- 12:15 **Panel-guided personalized medicine in metastatic breast and gynecological cancer: First experiences at the Comprehensive Cancer Centre Munich and clinical relevant changes over time** 3
 Oral Abstract SP: Rachel Wuerstlein (Germany)
- 12:30 **Contemporary picture of metastatic breast cancer: characteristics and outcomes of 22000 women from the ESME cohort 2008-2016** 4
 Oral Abstract SP: Elise Deluche (France)

Clinical Science Symposium: Latest Practices in Follow up of Patients

11:15 - 12:45 Goya

- Chair: Elizabeth Bergsten-Nordstrom (Sweden)
 Chair: Inez Vaz Duarte Luis. (France)
- 11:15 **Reasons and standards for follow up**
 Speaker: Inez Vaz Duarte Luis. (France)
- 11:30 **Apps and adherence: Overview**
 Speaker: Timo Schinköthe (Germany)
- 11:45 **Lifestyle/Exercise - for preventing recurrence and improving QOL**
 Speaker: Melinda Irwin (USA)
- 12:00 **Complementary medicine**
 Speaker: Caroline Hoffman (United Kingdom)
1. To identify complementary medical approaches proven to support people with breast cancer
 2. To discuss research for the benefit of complementary medicine in supporting symptoms and side effects of breast cancer and its treatments
 3. To discuss research evidence for complementary medicine in supporting living well with breast cancer
- 12:15 **Patient perspective - how individual patients manage follow up**
 Speaker: Barbara Klein (Italy)



- 12:30 **Trends in incidence, mortality, survival and treatment of primary invasive breast cancer in the Netherlands for women diagnosed between 1989–2017** 5
 Oral Abstract SP: Iris Kramer (Netherlands)

Young Investigators Session: Round Table Discussions

13:30 - 14:30

Room 129-130

Introduction to the session

To be announced ()

Young investigators can discuss difficult cases or struggles from clinics on how to treat their patients with a senior or young expert

Table 1

Local treatment

Moderator: Isabel T. Rubio (Spain)

Local treatment

Moderator: Icro Meattini (Italy)

Table 2

Elderly patients

Moderator: Etienne Brain (France)

Table 3

Young Patients (+ fertility)

Moderator: Matteo Lambertini (Italy)

Table 4

De-escalation and escalation of systemic therapy

Moderator: Fátima Cardoso (Portugal)

Table 5

Oligometastatic disease


Moderator: Jens Ricke (Germany)

Poster in the Spotlight: Poster in the Spotlight I

13:30 - 14:00

Poster Area/Exhibition Hall

- Moderator: David A. Cameron (United Kingdom)
- PB-001 **Salivary metabolomics with artificial intelligence-based methods for breast cancer detection and subtype prediction** 100
T. Murata, T. Yanagisawa, T. Kurihara, M. Kaneko, S. Ota, A. Enomoto, M. Tomita, M. Sugimoto, M. Sunamura, T. Hayashida, H. Jinno, Y. Kitagawa (Japan)
- Moderated discussion**
- PB-002 **Sense of coherence as predictor of quality of life in early breast cancer patients** 101
L. Hakamies-Blomqvist, N. Vähäaho, C. Blomqvist, P.L. Kellokumpu-Lehtinen, R. Huovinen, T. Saarto, C. Hakulinen (Finland)
- Moderated discussion**
- PB-003 **Does mesh improve patient satisfaction and health-related quality of life after implant-based breast reconstruction? A multicentre prospective cohort study** 102
E. Sewart, N. Turner, E. Conroy, R. Cutress, J. Skillman, L. Whisker, S. Thrush, N. Barnes, C. Holcombe, S. Potter (United Kingdom)
- Moderated discussion**



Plenary Session: Keynote Lecture, Best and Late Breaking Abstract Presentations

14:45 - 16:15

Picasso

- Chair: Nadia Harbeck (Germany)
 Chair: Emiel J. T. Rutgers (Netherlands)
- 14:45 **PROMs, PREMs: Problems and Solutions**
 Keynote Speaker: Amylou Dueck (USA)
- 15:15 **Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial** 6
 Oral Abstract SP: Otto Metzger (USA)
- 15:30 **The risk of cardiovascular disease in irradiated breast cancer patients: the role of cardiac calcifications and adjuvant treatment** 7
 Oral Abstract SP: Helena Verkooijen (Netherlands)
- 15:45 **Bridging the age gap: improved decision making for older women with early breast cancer, a cohort and cluster randomised analysis**
 Oral Abstract SP: Lynda Wyld (United Kingdom)
- Impacts of omission of breast cancer surgery in older women with ER+ early breast cancer. A risk stratified analysis of survival and quality of life outcomes** 8A
 Lynda Wyld (United Kingdom)
- Cluster randomised trial to evaluate the clinical benefits of decision support interventions for older women with operable breast cancer.** 8B
 Lynda Wyld (United Kingdom)
- 16:00 **to be announced**

Debate: This House Believes That no Patient, with Luminal A like Node Positive Early Breast Cancer, Needs Chemotherapy

16:30 - 17:30

Picasso


- Moderator: Etienne Brain (France)
- 16:30 Speaker in favour: Christos Sotiriou (Belgium)
- 16:45 Speaker against: Wolfgang Janni (Germany)
- 17:00 Seconder in favour: Sabine Linn (Netherlands)
- 17:10 Seconder against: Patrick Neven (Belgium)
- 17:20 **Voting/Conclusion**

Best Practice Session: End of Life Care

16:30 - 17:30

Miro

- Chair: Sema Erdem (Turkey)
- 16:30 **Palliative care specialist: prognostication**
 Expert: Rachel Wuerstlein (Germany)
- 16:40 **Medical Oncologist**
 Expert: Suzette Delalogue (France)



- 16:50 **Patient and family**
Expert: Eva Masel (Austria)
Nurse (Panel Member)
Expert: Deborah Fenlon (United Kingdom)
- 17:00 **Panel discussion**

Society Session: European Society of Pathology (ESP) - Breast Cancer TNM 8 - The Pathologists' Perspective

16:30 - 18:00

Goya

- Chair: Zsuzsanna Varga (Switzerland)
Chair: Tibor Tot (Sweden)
- Introduction**
- 16:30 **The importance of reproducible staging of breast cancer**
Speaker: Zsuzsanna Varga (Switzerland)
- 16:50 **Stage migration in case of genetic testing**
Speaker: Gabor Cserni (Hungary)
- 17:10 **LCIS: benign or malignant**
Speaker: Maria Pia Foschini (Italy)
- 17:30 **The problems**
Speaker: Tibor Tot (Sweden)
- 17:50 **Discussion**

Young Investigators Session: Scientific Small Group Discussions

16:30 - 18:00

Room 129-130

Introduction to the session

To be announced ()

The small group discussion will focus on research proposals/trial ideas that young investigators may have. Each small group will be under the supervision of a senior or young expert that can also help frame the ideas and suggest finished trials from which data could be effectively used to explore new research questions.

Table 1

Biomarkers

Moderator: Michail Ignatiadis (Belgium)

Table 2

Gene expression signatures/prognostic factors; further exploring the mindact database

Moderator: Emiel J. T. Rutgers (Netherlands)

Table 3

Male breast cancer


Moderator: Fátima Cardoso (Portugal)

Table 4

Using cancer registry data for research

Moderator: Jonas Bergh (Sweden)

Table 5



Health economics

Moderator: Valesca Retel (Netherlands)

Poster Session: Follow up

Poster Area/Exhibition Hall

PB-008	Metachronous breast cancer: An observational study in a single institution W.P. Lee, <u>S.S. Shetty</u> , C.M.J. Seah, J.W.C. Kam, S.M. Tan (Singapore)	107
PB-009	Improvement of recurrent rates and survival in patients with primary breast cancer according to subtypes <u>M. Nakano</u> , R. Nishimura, T. Osako, Y. Okumura, M. Fujisue, N. Arima (Japan)	108
PB-010	Characteristics of ipsilateral breast tumor recurrence after breast conserving surgery : Single center experience <u>H. Lee</u> , M. Lee, J. Cho, S. Kang (South Korea)	109
PB-011	Do patients with breast cancer receive the optimal personalized follow up? <u>J. Van Hove</u> , J. Ankersmid, L. Strobbe, M. Velting, D. Sprengers, J. Verloop, R. Schrijer, B. Kistemaker, S. Siesling (Netherlands)	110
PB-012	Long-term prognosis correlates with residual disease in breast and axillary nodes but not with initial nodal status: Follow-up data from the Swedish prospective multicenter trial evaluating sentinel lymph node biopsy in the neoadjuvant setting <u>L. Zetterlund</u> , F. Celebioglu, J. Frisell, J. De Boniface (Sweden)	111
PB-013	Development of an information standard for breast cancer in the Netherlands <u>J. Verloop</u> , F. Klijn, T. Van Vegchel, M. Bessems, C. Meeuwis, L. Wijers, A. Honkoop, J. Heijns, S. Siesling, X. Verbeek (Netherlands)	112
PB-014	PD-L1 and HSP-70 molecules are part of immunosuppressive environment in the deep layer of the lymphocyte predominant breast cancer (LPBC) <u>A. Car Peterko</u> , K. Rajković Molek, D. Veljković Vujaklija, P. Zujic Valković, I. Belac Lovasić, F. Lovasić, E. Mustać, M. Avirović, (Croatia)	113
PB-016	Prognosis according to the timing of recurrence in breast cancer <u>S. Jung</u> , S.Y. Bae, H.W. Yang, J.W. Bae (South Korea)	115

Poster Session: Local Regional Treatment - Surgery

Poster Area/Exhibition Hall

PB-017	Vacuum intraoperative specimen mammography: A novel technique M.G. Baù, <u>A. Surace</u> , G. Gregori, C. De Sanctis, V. Marra, C. Marengo, D. Tota, F. Borrella, C. Benedetto, M.P. Mano (Italy)	116
PB-018	Angiosome theory findings using new protocol of CT-angiography improves outcomes in DIEP-flap reconstruction surgery in breast cancer patients <u>R. Pesotsky</u> , P. Krivorotko, P. Kalinin, K. Zernov, A. Bessonov, L. Gigolaeva, A. Emelyanov, S. Yerechshenko, K. Kozyreva, E. Munaeva, Z. Aseeva, N. Boiko, V. Semiglazov (Russian Federation)	117
PB-019	The value of removing more than one sentinel node in breast cancer <u>J. Lopes Cardozo</u> , J. Vanhomerig, S. Donkervoort (Belgium)	118
PB-020	Long term survival outcomes of "LORIS-low risk" ductal carcinoma in-situ from a territory-wide cancer registry in Hong Kong <u>M. Co</u> , A. Kwong (Hong Kong)	119
PB-021	Predictors of surgical margin involvement in breast cancer surgery <u>A. Goikoetxea Urdiain</u> , I. Eguaras Córdoba, I. Otegi Altolagirre, N. Moras Perez, M.A. Sanz de Pablo, C. Artieda Soto, P. Armendáriz Rubio (Spain)	120

PB-022	Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for small breast carcinomas <u>T. Kinoshita</u> , M. Takahashi, T. Fujisawa, N. Yamamoto, H. Doihara, S. Ohtani, M. Takahashi, K. Aogi, T. Ohnishi, S. Takayama, M. Futamura (Japan)	121
PB-023	Non-intervention vs. surgical interventions in (Low-Risk) Ductal Carcinoma In Situ: A DCIS multi-state model for decision analytics <u>D. Byng</u> , V. Retèl, M. Schaapveld, J. Wesseling, W. Van Harten (Netherlands)	122
PB-024	Psycho-social assessment of post-surgery outcomes after breast reconstruction surgery <u>L. Busheri</u> (India)	123
PB-025	Combined iodinated radiographic contrast and Tc99 radioisotope (i-ROLL) as technical improvement for the preoperative localization of non-palpable breast lesions: A comparative study with ROLL <u>M. Medarde Ferrer</u> , J. Del Riego Ferrari, O. Aparicio Rodriguez, J.C. Martin Miramón, V. Lucas Guerrero, A. Martin Oloriz, S. Navarro Soto (Spain)	124
PB-026	Quality of life improvement and pain reduction in implant-based breast reconstruction by means of selective pectoralis major muscle denervation <u>M. Bernini</u> , I. Meattini, S. Sordi, L. Orzalesi, J. Nori Cucchiari, V. Scotti, I. Desideri, S. Bianchi, L. Livi (Italy)	125
PB-027	Good cosmetic outcome after vacuum assisted excision of benign breast lesions <u>E. Van De Voort</u> , T. Klem, G. Struik, E. Birnie, R. Sinke, A. Ghandi (Netherlands)	126
PB-028	Breast Lesion Excision System as a treatment method for small invasive breast cancers <u>W. Sanderink</u> , L. Strobbe, P. Bult, W. Vreuls, I. Sechopoulos, N. Karssemeijer, R. Mann (Netherlands)	127
PB-029	Accurate axillary staging by superparamagnetic iron oxide-enhanced MR imaging as an alternative to sentinel node biopsy in breast cancer <u>K. Motomura</u> , S. Hashidume, Y. Tabuchi, M. Kouda, S. Kawamoto (Japan)	128
PB-030	SPIO-guided Sentinel Lymph Node Biopsy (SLNB) in early Breast Cancer – first monoinstitutional data and perspectives <u>S. Paepke</u> , M. Kiechle, M. Karsten, J.U. Blohmer, G. Schmidt, J. Stassek, T. Kühn, M. Thill (Germany)	129
PB-031	Association of axillary lymph node evaluation with survival in women aged 70 years or older with breast cancer <u>S. Luo</u> , J. Zhang, C. Song (China)	130
PB-032	Mesh-Pocket supported prepectoral implant-based breast reconstruction: Final results of a retrospective analysis <u>S. Paepke</u> , M. Kiechle, C. Ankel, R. Ohlinger, M. Thill, K. Kelling, K. Baumann, T. Pursche, H.J. Strittmatter, A. Faridi (Germany)	131
PB-033	How I do it: Lymphatic mapping and sentinel lymph node biopsy with Indocyanine Green in Breast Cancer patients, a prospective trial experience <u>E. York</u> , R. Corripio S., C. Zapata C., C. Escabias, I. Osorio S., J. Sánchez M, J. Diez S, P. Quadros B, J. Diaz D. (Spain)	132
PB-034	Oncological safety of oncoplastic breast conserving surgery- compare with conventional surgery <u>Y. Kim</u> , W. Han (South Korea)	133
PB-035	Oncoplastic breast-conserving surgery offers low local recurrence rates and excellent survival rates despite worse tumor characteristics <u>C. André</u> , C. Holsti, A. Svenner, I. Oikonomou, H. Ikonomidis Sackey, M. Appelgren, A. Johansson, J. De Boniface (Sweden)	134
PB-036	Omission of axillary dissection after neoadjuvant chemotherapy for node-positive primary breast cancer <u>A. Matsumoto</u> , U. Yasuko, D. Tsukahara, H. Jinno (Japan)	135
PB-037	Neoadjuvant chemotherapy is not a contraindication for nipple-sparing mastectomy: definitive results <u>E. Zarba Meli</u> , M.T. Lacaria, L. Costarelli, E. Manna, M. Mauri, P. Scavina, M. Minelli, D. Spallone, M. La Pinta, A. Burza, U. De Paula, A.D. Andrulli, L. Broglia, T. Ponzani, G. Cortese, A. Loreti, L. Fortunato (Italy)	136

PB-038	Variation in the rates of surgical treatment of older women with operable breast cancer between UK breast units: analysis of the Bridging the Age Gap Study <u>J. Morgan</u> , G. Holmes, C. Martin, S. Ward, S. Walters, K.L. Cheung, R. Audisio, M. Reed, L. Wyld (United Kingdom)	137
PB-039	Quality of life outcomes following breast surgery in older women with operable breast cancer: analysis of the Bridging the Age Gap study <u>J. Morgan</u> , G. Holmes, C. Martin, S. Ward, S. Walters, K.L. Cheung, R. Audisio, M. Reed, L. Wyld (United Kingdom)	138
PB-040	Patient Reported Outcome and cosmetic evaluation following implant-based breast-reconstruction with a titanized polypropylene mesh: a prospective clinical study in 269 patients <u>M. Thill</u> , E. Klein, A. Faridi, A. Meiré, C. Gerber-Schäfer, C. Baumann, J.U. Blohmer, C. Mau, S. Tofall, E. Nolte, H.J. Strittmatter, R. Ohlinger, S. Paepke (Germany)	139
PB-041	Evaluation of the breast lesion excision system, a percutaneous, vacuum assisted, intact- specimen, breast biopsy device <u>G. Kinoglou</u> , V. Antoniou, C. Kalyvopoulos, N. Vrenzos (Greece)	140
PB-042	Hospital variation in the use of Sentinel Lymph Node Biopsy for patients with a biopsy diagnosis of ductal carcinoma in situ C. Meurs, M. Menke-Pluijmers, S. Sabine, <u>P. Westenend</u> (Netherlands)	141
PB-043	Radioactive seed versus wire-guided localization for ductal carcinoma in situ of the breast: comparable resection margins <u>M.C. Agahozo</u> , S.A.M. Berghuis, E. Van den Broek, L.B. Koppert, I.M. Obdeijn, C.H.M. Van Deurzen (Netherlands)	142
PB-044	Predicting lymph node metastases for biopsy diagnosis ductal carcinoma in situ: the DCIS-met model C. Meurs, J. Van Rosmalen, M. Menke-Pluijmers, S. Siesling, <u>P. Westenend</u> (Netherlands)	143
PB-045	Optimization of wire-guided technique with bracketing reduces resection volumes in breast-conserving surgery for early breast cancer <u>Y. Civil</u> , K. Duvivier, P. Perin, A. Baan, S. Van der Velde (Netherlands)	144
PB-046	Endoscopic nipple-areolar complex sparing mastectomy : a single institution's early experience <u>H.Y. Lee</u> , C. Young Woo, Y. Da Young, S. Gil Soo (South Korea)	145
PB-047	A Randomised Controlled Trial (RCT) of 3-dimensional simulation of the aesthetic outcome of Breast Conserving Treatment (BCT) <u>A. Godden</u> , A. Micha, C. Pitches, L. Wolf, K. Krupa, P. Barry, J. Rusby (United Kingdom)	146
PB-048	Predicting postoperative complications in older patients with breast cancer A. Lemij, <u>W. Van Der Plas-Krijgsman</u> , E. Bastiaannet, J. Merkus, T. Van Dalen, A. Vulink, L. Van Gerven, O. Guicherit, J. Portielje, G.J. Liefers, N. De Glas (Netherlands)	147
PB-049	Breast cancer in elderly patients: are we choosing wisely? A critical review of the breast unit of Trieste F. Giudici, S. Scomersi, T. Coren, M. Tonutti, C. Rizzardi, A. Dell'Antonio, M. Fezzi, F. Dore, R. Ceccherini, A. Schiattarella, V. Milan, F. Zanconati, <u>M. Bortul</u> (Italy)	148
PB-050	Cosmetic outcome and symmetry for patients who have undergone bilateral therapeutic mammoplasty for breast cancer <u>K. Gulis</u> , P.O. Bendahl, T. Svensjö, L. Rydén (Sweden)	149
PB-051	A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer M. Beek, P. Gobardhan, E. Klompenhouwer, M. Menke-Pluijmer, P. Steenvoorde, J. Merkus, H. Rutten, <u>A. Voogd</u> , E. Luiten (Netherlands)	150
PB-052	Sentinel node biopsy before and after the introduction of sentimag at a tertiary academic breast unit <u>F. Malherbe</u> , L. Roodt, F. Noor, K. Chibuye, L. Cairncross (South Africa)	151
PB-053	Which are the predictive factors for the status of resection margins in breast conserving surgery and how they influence the overall survival and local recurrence? <u>R. Georgescu</u> , O. Bauer, Z. Benedek, M.F. Coros, R. Oancea, F. Tutuianu, M. Tigu, C. Radoi (Romania)	152
PB-054	Knowledge attitude and practice of surgeons for breast conserving surgery: results from an Indian cohort	153

	<u>N. Nair</u> , A. Tondare, R. Hawaldar, V. Parmar, K. Kirti, G. Chitkara, S. Joshi, P. Thakkar, R. Badwe (India)	
PB-055	Current clinical practice and determinants of the use of delayed breast reconstruction in the Netherlands <u>P. Van Egdom</u> , K. De Ligt, MSc, L. De Munck, H. Rakhorst, M. Mureau, L. Koppert, S. Siesling (Netherlands)	154
PB-056	Clinical, imaging and pathology factors related to residual axillary disease after neoadjuvant treatment <u>M. Vernet-Tomas</u> , S. Perera, J. Castellà, B. Fabregó, N. Argudo, M. Jiménez, M. Segura, R. Alcantara, M. Pitarch, N. Arenas, F. Plancarte, I. Vázquez, L. Comerma, P. Nicolau (Spain)	155
PB-057	The impact of radiotherapy on patient-reported outcomes of immediate implant-based breast reconstruction: Results of a prospective multicentre cohort study <u>E. Sewart</u> , N. Turner, E. Conroy, R. Cutress, J. Skillman, L. Whisker, S. Thrush, N. Barnes, C. Holcombe, S. Potter (United Kingdom)	156
PB-058	P53 and axillary tumor burden in breast cancer <u>P. Nicolau</u> , N. Argudo, M. Jimenez, M. Segura, P. Maso, I. Vazquez, L. Comerma, S. Servitja, M. Martinez, T. Martos, D. Casadevall, R. Alcantara, F. Plancarte, M. Pitarch, N. Arenas, X. Sanz, N. Rodriguez, M. Algara, M. Vernet-Tomás (Spain)	157
PB-059	Personalized treatment in the elderly after a multidimensional geriatric assessment <u>M. Ghilli</u> , R. Antognoli, V. Camilleri, F. Falossi, E. Rossetti, L. Colizzi, V. Coli, M. Lo Russo, L. Fustaino, A. Quattrini Li, G. Baldetti, M.D. Mariniello, A. Fontana, C. Marini, S. Spagnesi, G. Fanelli, C. Papi, S. Paoletti, F. Monzani, M. Roncella (Italy)	158
PB-060	Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer <u>Y. Andersson</u> , J. Frisell, L. Bergkvist, J. De Boniface (Sweden)	159
PB-061	The process of EUSOMA (European Society of Breast Cancer Specialists) improves the quality of breast cancer care: the experience of an Italian EUSOMA certificated Breast Unit <u>A. Bonetti</u> , D. Gazzani, A. Dai Prè, R. Sandrini, M. Governa, A. Zogno, A. Remo, F. Greco, E. Molinari, G. Aguzzi, D. Signorelli, D. Caprara, L. Costa, C. Zanella, M. Signorini, A. Mercanti, J. Giuliani, S. Majori, F. Moretti (Italy)	160
PB-062	Women diagnosed with Ductal Carcinoma In Situ (DCIS) and healthcare providers' views on active surveillance for DCIS. Results from focus groups and in-depth interviews <u>E. Engelhardt</u> , D. Byng, K. Klaver, M. Gerritsma, E. Verschuur, M. Van Oirsouw, J. Wesseling, F. Van Duijnhoven, V. Retèl, E. Bleiker (Netherlands)	161
PB-063	Breast conserving surgery in breast cancer after neoadjuvant chemotherapy – opportunity of radioopaque tumor marking clips <u>G. Iancu</u> , L. Mustata, L. Tuinea, A. Corha, B. Median, G. Peltecu, D. Median (Romania)	162
PB-064	Usefulness of locoregional nerve blocks in breast surgery. A comparative study <u>A. Fancellu</u> , T. Perra, P. Terragni, P. Arghittu, P. Cottu, M.C. Ninniri, G. Deiana, C. Piredda, V. Sanna, A. Porcu (Italy)	163
PB-065	Multidisciplinary breast cancer guideline in the Netherlands: modular revisions aiming for improved personalized breast cancer care <u>J. Van Hoeve</u> , T. Van Vegchel, D. Hairwassers, L. Boersma, I.M. Obdeijn, M. Van der Sangen, L. Strobbe, T. Smit-Hoeksma, A. Honkoop, J. Maduro, J. Verloop, S. Siesling, C. Smorenburg (Netherlands)	164
PB-066	Versatility, clinical outcomes and mammographic follow-up of Chest Wall Perforator Flaps (CWPF): a single-centre experience <u>T. Seddon</u> , D. Dragoumis, M. Al-Attar, K. Valassiadou (United Kingdom)	165
PB-067	Comparative accuracy of preoperative tumour size of invasive ductal carcinoma on Magnetic Resonance Imaging, Digital Breast Tomosynthesis, Ultrasound and Computed Tomography: Radiologic-pathologic incongruence and clinical implications <u>A.V. Parab</u> , S. Khan, D. Bandara, S. Khawaja, Y. Sharaiha, A. Munir, A. Moalla, S. Holt, A. Huws (United Kingdom)	166

PB-068	Retrospective analysis of survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis <u>S. Xianfu</u> , W. Yingjie, H. Tao (China)	167
PB-069	Internal audit of an Indian breast oncosurgery unit using EUSOMA guidelines <u>S. Gupta</u> , N. Gupta, G. Kadayaprath (India)	168
PB-070	Selective axillary dissection after axillary reverse mapping in node positive breast cancer patients to prevent breast cancer related lymphedema. The issue of safety. M. Gennaro, <u>S. Segattini</u> , C. Listorti, I. Maugeri, V. Capizzi, M. Maccauro, S. Folli (Italy)	169
PB-071	Predictors of seroma formation after breast cancer surgery <u>H. Vos</u> , M. Reymen, L. Vandezande, T. Karman, A. Van Vugt, S. Vanderheyden, I. Nevelsteen, A. Smeets (Belgium)	170
PB-072	Nationwide population-based study: patterns of care in young breast cancer patients in the Netherlands <u>N. Maliko</u> , N. Bijker, M. Bos, M.J. Vrancken Peeters (Netherlands)	171
PB-073	Defining a 'dedicated' breast cancer team <u>N. Maliko</u> , N. Bijker, M. Wouters, M.J. Vrancken Peeters (Netherlands)	172
PB-074	Predictive factors involved in determining response to neoadjuvant chemotherapy in breast cancer and impact of response on 5 years disease free survival and overall survival <u>B. Rehman</u> , M.A. Parvaiz (Pakistan)	173
PB-075	Male breast cancer: A high volume centre experience <u>F. Combi</u> , S. Papi, E. Palma, A. Gambini, A. Andreotti, G. Esposito, G. Tazzioli (Italy)	174
PB-076	Surgical margin involvement increases distant recurrence, not just local recurrence S. Michael, S. Bowers, J. Ooi, M. Absar, S. Ellenbogen, <u>N. Bundred</u> (United Kingdom)	175
PB-077	Size discrepancy of residual tumor between post chemotherapy sonography and on post excision histopathology after Neo adjuvant chemotherapy and its impact on 5 years disease free survival M.A. Parvaiz, N. Khanum, B. Rehman, M.Z. Chuadhary, <u>N. Javed</u> , A.I. Khan, S. Afzal, R. Naheed, J. Mohsin (Pakistan)	176
PB-078	Trends of incidence and management of lobular carcinoma in situ compared with ductal carcinoma in situ: a Korean breast cancer registry analysis <u>J. Min</u> , E.T. Kim, M.C. Chang, K.T. Hwang (South Korea)	177
PB-079	Outcomes of magseed localisation of non- palpable breast lesions in a large university hospital A. Gaber, M. Al-Attar, S. Pilgrim, M. Hoosein, <u>M. Kaushik</u> (United Kingdom)	178
PB-080	A human-derived acellular dermal matrix for breast reconstruction: The first European experience <u>F. Marongiu</u> , D. De Tullio, D. Tognali, P. Nensor, S. Pasquali, A. Sibilio, R. Sgarzani, M. Mingozzi, F. Buggi, A. Curcio (Italy)	179
PB-081	Young age as an independent prognostic factor in breast cancer <u>R. Georgescu</u> , C. Radoi, R. Oancea, M. Tigu, S. Rusu, N. Suci, M.F. Coros, O. Bauer (Romania)	180
PB-082	Do surgical margins matter after mastectomy? A systematic review and meta-analysis J. Bundred, S. Michael, S. Bowers, N. Barnes, Y. Jauhari, D. Plant, T. Maishman, R. Cutress, B. Holleczeck, D. Dodwell, <u>N. Bundred</u> (United Kingdom)	181
PB-083	Axillary management in patients with breast cancer and positive axilla at diagnosis <u>M. Jimenez Gomez</u> , V. Vega Benitez, I. Gutierrez Giner, P. Pérez Correa, J.R. Hernández Hernández (Spain)	182
PB-084	Accuracy of Magnetic Localisation device placement and retrieval in breast cancer patients from a single internationally Accredited Breast Centre in Johannesburg South Africa <u>C. Benn</u> , V. Shaw, P. Ilunga, F.Z. Rahiman, A. Jogee, J. Belloni (South Africa)	183
PB-086	Short-term outcome and complications rate after immediate breast reconstruction with implants and acellular dermis <u>V. Bjelic-Radiscic</u> , E. Kirchhoff, C. Leidl, E. Trapp, D. Ulrich (Germany)	185

PB-087	The enduring rise of the contralateral prophylactic mastectomy: population trends in Ontario, Canada <u>L. Findlay-Shirras</u> , I. Lima, G. Smith, M. Clemons, J. Hilton, A. Arnaout (Canada)	186
PB-088	Psychosocial outcomes following contralateral prophylactic mastectomy in women with unilateral, nonhereditary breast cancer <u>D. Lim</u> , H. Retrouvey, I. Kerrebijn, K. Butler, A.C. O'Neill, J. Escallon, T. Cil, T. Zhong, S.O. Hofer, D.R. McCready, K. Metcalfe (Canada)	187
PB-089	Outcomes of breast cancer patients with nodal micrometastasis treated with sentinel lymph node biopsy versus axillary lymph node dissection <u>G. Kusumawidjaja</u> , S.Z. Lim, B.K.T. Tan, S.Y. Tan, J.L. Hamzah, P. Madhukumar, W.S. Yong, C.Y. Wong, Y. Sim, G.H. Lim, S.H. Lim, S.M. Tan, F.Y. Wong, V.K.M. Tan (Singapore)	188
PB-090	Sentidose Trial: Optimizing dose and injection timing in magnetic sentinel node detection for early breast cancer <u>A. Karakatsanis</u> , L. Pistoli, R. Olofsson Bagge, A. Hersi, C. Luberth Dussan, F. Nilsson, S. Eriksson, F. Wärnberg (Sweden)	189
PB-091	Symptomatic presentation and involved margins lead to Ductal Cancer In Situ recurrence S. Michael, S. Bowers, J. Ooi, M. Absar, S. Ellenbogen, <u>N. Bundred</u> (United Kingdom)	190
PB-092	Magseed localisation for loco-regional breast and lymph node recurrences. Placement prior to chemotherapy allows focused removal of the initially diseased tissue <u>C. Benn</u> , V. Shaw, P. Ilunga, A. Jogee, D. Van Loggerenberg (South Africa)	191
PB-093	Innovative magnetic tracers for sentinel node detection in primary breast cancer surgery and after neoadjuvant therapy <u>K. Rauš</u> , A. Faridová (Czech Republic)	192
PB-094	Did the BOOG 2013-08, which examines the value of omission of the sentinel lymph node in cT1-2 breast cancer treated with BCT, induce a change in axillary staging and treatment? <u>E. Colier</u> , S. Pessers, R. Vos, M. Smidt, L. Van Roozendaal (Netherlands)	193
PB-095	Endofascial axillary dissection - a novel method to reduce seroma formation <u>S. M.</u> , P. Augustine, R. Bhargavan, K. Cherian, S. S (India)	194
PB-096	How many sentinel lymph nodes in addition to the clipped node are needed to accurately stage the axilla after neoadjuvant treatment in breast cancer? <u>C. Siso</u> , A. Esgueva, J.P. Salazar, M. Espinosa-Bravo, I.T. Rubio (Spain)	195
PB-097	Risk of contralateral breast cancer and ovarian cancer in BRCA1 founder mutation (5382insC or 4154delA) carriers with primary breast cancer <u>P. Loza</u> , A. Irmejs, J. Maksimenko, G. Trofimovics, J. Gardovskis, E. Miklasevics, Z. Daneberga (Latvia)	196
PB-098	Safety, feasibility and clinical outcomes of robotic nipple sparing mastectomy: A systematic review of the literature <u>T. Cil</u> , F. Angarita, M. Castelo, D. McCready, M. Englesakis (Canada)	197
PB-099	The role of cryoablation in patients with metastatic breast cancer at the time of presentation <u>A. Fancellu</u> , L. Melis, N. Ballicu, P. Meloni, V. Sanna, A. Porcu, C. Pusceddu (Italy)	198
PB-100	Direct or delayed oncoplastic reconstruction after wide local excision for breast cancer in breast conserving therapy: A single centre cohort study of 252 cases C.S. Geluk, <u>A. Van Loevezijn</u> , M.J.T.F.D. Vrancken Peeters, F.H. Van Duijnhoven, M.J. Hoornweg (Netherlands)	199
PB-101	Importance of intraoperative surgical margin assessment for positive margin diagnosis in breast cancer-conserving surgery <u>A. Goikoetxea Urdiain</u> , P. Armendáriz Rubio, N. Moras Pérez, C. Artieda Soto, S.D.P. Miguel Angel, V.P. Leyre (Spain)	200
PB-102	Axillary staging with supine 18F-FDG PET/CT is useful in breast cancer patients undergoing tailored axillary treatment after neoadjuvant systemic therapy according to the MARI protocol <u>A. Van Loevezijn</u> , M.L. Donswijk, M.P.M. Stokkel, F. Van Duijnhoven, M.J.T.F.D. Vrancken Peeters (Netherlands)	201

PB-103	Blood group and save samples for elective breast surgery: An unnecessary cost?	202
	<u>T. Chouari</u> , K. Rangarajan, T. Howe, H. Osman, R. Daoud, I. Laidlaw, I. Karat (United Kingdom)	
PB-104	Realising true day-case breast surgery : A review of factors influencing same-day discharge (SDD)	203
	<u>T. Chouari</u> , K. Rangarajan, H. Osman, R. Daoud, I. Laidlaw, M. Uhercik, I. Karat (United Kingdom)	
PB-105	Nipple sparing mastectomy (nsm) after surgical delay (sd) and prepectoral direct to implant (dti) reconstruction with polyurethane prostheses: preliminary results	204
	<u>A. Loreti</u> , B. Fanelli, D. Spallone, F. Arelli, M. Marcasciano, O. Abate, C. Latini, M. De Carli, M. La Pinta, E. Manna, E. Zarba Meli, L. Fortunato (Italy)	
PB-106	Epidemiological characteristics of invasive lobular carcinoma of the breast in North Africa: example of a Tunisian population	205
	<u>M. Hadoussa</u> , Y. Yahyaoui, N. Boujelbene, F. Letaief, A. Mokrani, K. Meddeb, N. Cheraiet, A. Gabsi, H. Raies, K. Mrad, A. Mezlini (Tunisia)	
PB-107	MRI prediction of response to neoadjuvant chemotherapy in breast cancer: comparison between patients with and without mammographic calcifications	206
	<u>E. Carmon</u> , B. Simor, B. Mali, T. Sella (Israel)	
PB-108	Definitive treatment of premalignant lesions of the breast with "double crown": An innovative percutaneous technique	207
	<u>O. Aparicio</u> , M. Medarde, A. Martin, L. Tortajada, J. Del Riego, M. Sentis, S. Navarro (Spain)	
PB-109	Automatic detection of perforators for microsurgical reconstruction and correlation with patient's body-mass index	208
	<u>D. Pinto</u> , C. Mavioso, R. J. Araujo, H. P. Oliveira, J. C. Anacleto, M.A. Vasconcelos, P. Gouveia, N. Abreu, C. Alves, J. S. Cardoso, M.J. Cardoso, F. Cardoso (Portugal)	

Poster Session: Nursing

Poster Area/Exhibition Hall

PB-110	Clinical decision trees provide a means for systematic registration and evaluation of multidisciplinary team recommendations	209
	<u>M. Hendriks</u> , X. Verbeek, J. Van Manen, S. Van der Heijden, S. Go, G. Gooiker, T. Van Vegchel, S. Siesling, A. Jager (Netherlands)	
PB-111	Cryotherapy to prevent doxorubicin-associated oral mucositis	210
	<u>L. Brink-Mosch</u> , M.M. Stuiver, E. Pan van der, C.H. Smorenburg (Netherlands)	
PB-112	Implementation of a nurse-led wound care consultation after breast cancer surgery	211
	<u>L. Vandezande</u> , H. Vos, T. Karman, M. Reymen, M. Dieu, S. Vanderheyden, A. Van Vugt, A. Smeets, I. Nevelsteen (Belgium)	
PB-113	Process evaluation of the bridging the age gap in breast cancer decision support intervention cluster randomised trial	212
	<u>M. Burton</u> , K. Lifford, L. Wyld, F. Armitage, K. Collins, M. Reed, K. Brain, A. Edwards (United Kingdom)	
PB-114	Improving pain outcomes after breast cancer surgery using a novel psychoeducational intervention	213
	<u>M. Alwan</u> , S. Down (United Kingdom)	

Poster Session: Supportive and Palliative Care Including End of Life Treatment

Poster Area/Exhibition Hall


PB-116	The Effect of Scalp-Cooling System on the Prevention of Alopecia after chemotherapy <u>H. Maseki</u> , T. Kinoshita, A. Matsui, Y. Iwata, H. Harada, M. Sasahara, Y. Ichimura, Y. Murata, S. Urakami, S. Seki, T. Oishi, Y. Isobe (Japan)	215
PB-120	Use of an Alfa-lipoic, Methylsulfonylmethane, Boswellia Serrata and Bromelain Dietary Supplement for Aromatase Inhibitors-related Arthralgia Management (AIA): a prospective phase II trial (NCT04161833) I. Desideri, S. Lucidi, P. Garlatti, V. Lorenzetti, C. Ciabatti, F. Terziani, V. Scotti, P. Bonomo, G. Francolini, <u>I. Meattini</u> , L. Livi (Italy)	219
PB-121	Distress and effectiveness of Brief Cognitive Behaviour Intervention for patients with family history of cancer <u>J. Srivastava</u> , S. Kaushik, H. Shukla (India)	220
PB-122	Theory of mind deficit in women with breast cancer and depression: a comparative study from India <u>S. Ostwal</u> , A. Datta (India)	221
PB-123	The effect of a chamomile compound on pain and heaviness in breast cancer patients with Lymphedema: a double-blind and randomized controlled trial Z. Sheikhi-Mobarakeh, <u>P. Mokhtari Hesari</u> , G. Heydarirad, S. Fahimi, A. Montazeri (Iran)	222
PB-124	Symptom talk during clinic visits for treatment of breast cancer: do we get an accurate picture? <u>K. Mooney</u> , Professor, M. Whisenant (USA)	223
PB-125	Variation and efficacy of scalp cooling in Dutch hospitals among >5000 breast cancer patients <u>C. Van Den Hurk</u> , W. Dercksen, B. Vriens, H. Nortier, W. Breed (Netherlands)	224

Poster Session: Systemic Treatment

Poster Area/Exhibition Hall

PB-126	Administration of LHRH agonist as an adjuvant endocrine therapy for breast cancer is a risk factor of ovarian function recovery after switching from tamoxifen to aromatase inhibitor <u>H. Ishige</u> (Japan)	225
PB-127	Finding existing drugs potentially active against BRCA-mutated breast cancers: a literature-based approach <u>S. Crispino</u> , P. Pantziarka, L. Meheus, G. Bouche (Belgium)	226
PB-128	Dynamic monitoring of CD45-/CD31+/DAPI+ circulating endothelial cells aneuploid for chromosome 8 during neoadjuvant chemotherapy in locally advanced breast cancer <u>G. Ma</u> , T. Xia, X. Liu, S. Wang (China)	227
PB-130	Real-life use of 21-gene signature: A retrospective analysis of 46 cases from private practice <u>C. Bernard Marty, Mrs.</u> , J. Farnarier, L. Puyuelo, J. Capdet, S. Bringer, M. Martinez (France)	229
PB-131	Should chemotherapy in neoadjuvant setting in node positive breast cancers be guided by biology over magnitude of tumour burden? E. Provenzano, <u>E. Garreffa</u> , P. Wignarajah, N. Borkar, V. Psychogiou, A. Newton, J. Benson, P. Forouhi, L. Hughes-Davies, C. Wilson, K. McAdam, S. Russell, A. Agrawal (United Kingdom)	230
PB-132	Assessing the benefits and toxicities of platinum containing neoadjuvant chemotherapy in triple negative breast cancer K. Jarral, <u>K. Kancherla</u> , Z. Arif, S. Sharma, M. Kaushik (United Kingdom)	231
PB-133	Effects of chemotherapy on serum lipids in Chinese postoperative breast cancer patients <u>Y. Zhu</u> , L. Xiaolan, L. Qi, W. Xian, X. Tiansong, Y. Junzhe, W. Xingmeng, Y. Chaoran, C. Ruyun, Z. Kai, X. Tingyu, W. Bin, V. Jordee S, Z. Xiaoqiang (China)	232

PB-134	Relationship between magnetic resonance imaging of breast and pathological tumor response after neoadjuvant chemotherapy in breast cancer patients <u>H.J. Lee</u> , H.S. Kim, W.Y. Kim, J.B. Lee, S.U. Woo (South Korea)	233
PB-135	Management of early breast cancer by trastuzumab biosimilar: Insights from observational drug utilization registry <u>A.D. Dwary</u> (India)	234
PB-136	Pyrotinib in HER2-Positive local advanced or metastatic breast cancer patients: results from a retrospective study in real-world setting <u>Q. Wang</u> , C. Chen, Y. Wang, S. Sun, J. Cheng (China)	235
PB-137	Optimal duration and effectiveness of neoadjuvant endocrine therapy in breast cancer – Retrospective series <u>A. Konsoulova-Kirova</u> , J. Ribeiro, H. Gouveia, S.R. Volovat, B. Sousa, R. Marques, M.J. Brito, D. Pinto, P. Gouveia, M.A. Vasconcelos, E. Batista, M.J. Cardoso, C. Alves, F. Cardoso (Bulgaria)	236
PB-138	Quality of life (QL) in elderly breast cancer survivors. Effects of surgery. Global QL determinants <u>J.I. Arraras</u> , J.J. Illarramendi, A. Manterola, S. De la Cruz, G. Asin, E. Salgado, M. Campos, M. Barrado, B. Ibañez, U. Zarandona, M. Rico, M.A. Dominguez, A. Sola, E. Martinez (Spain)	237
PB-139	The optimal timing and duration of daily filgrastim for primary prevention of febrile neutropenia after TAC chemotherapy: Multicenter randomized open-label phase IV study <u>D. Kim</u> , Z. Kim, S.M. Hur, J.E. Lee, S.Y. Kim, C.W. Lim (South Korea)	238
PB-140	Compliance to adjuvant endocrine treatment – real world data from 1019 consecutive luminal breast cancer patients with long follow-up <u>C. Chamalidou</u> , S. Nasic, B. Linderholm (Sweden)	239
PB-141	Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: real life experience. <u>E. Kovalenko</u> , L. Manzyuk, V. Gorbunova, I. Kolyadina, L. Bolotina, L. Zhilyaeva, D. Ponomarenko, E. Karabina, G. Mukhametshina, A. Khasanova, R. Ekaterina, A. Safarova, A. Manikhas, M. Volkonsky, L. Kramskaya, T. Karandeeva, I. Suslova, N. Popova, I. Evstigneeva, I. Shumskaya (Russian Federation)	240
PB-142	Pathological Complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer S. Jung, <u>C.W. JEON</u> , J. Choi, D. Hyun, H. Lee, K. Kwon, H. Yoon (South Korea)	241
PB-143	Mantle cell lymphoma in the context of breast cancer <u>A. Vernadou</u> , D. Milowich, J. Bloch, N. Ketterer, L. De Leval, K. Zaman (Switzerland)	242
PB-144	A high rate of pathological complete response is possible by incorporating cisplatin in neoadjuvant therapy of locally advanced triple-negative breast cancer: a single-institution experience <u>J. Georgy</u> , A. Singh, A. Joel, R. Chacko, A. John, F. Ninan, A. Paul, G. John (India)	243
PB-145	Tumor-Infiltrating Lymphocytes: Predictive changes in tumor size after neoadjuvant treatment <u>J. Jimeno Fraile</u> , S. Hermana, S. Sánchez, L. Paz, J. Estévez, A. De Juan, J.T. Anchuelo, F. Hernanz (Spain)	244
PB-146	Diagnostic performance of noninvasive imaging for assessment of axillary pathologic complete response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis <u>S. Samiej</u> , C. De Mooij, M. Lobbes, K. Keymeulen, T. Van Nijnatten, M. Smidt (Netherlands)	245
PB-147	Quality of life in postmenopausal breast cancer patients with localized disease after 5 years of endocrine treatment: a prospective study <u>J.I. Arraras</u> , J.J. Illarramendi, A. Manterola, E. Salgado, G. Asin, S. De la Cruz, M. Barrado, M. Campos, B. Ibañez, U. Zarandona, M. Rico, R. Vera (Spain)	246
PB-148	The gene expression profile in clinically node negative T1-2 breast cancer patients: Its additional value in case of sentinel lymph node biopsy is not performed. <u>E. Colier</u> , M. Vane, L. Roozendaal, M. De Boer, S. Siesling, M. Smidt (Netherlands)	247



PB-149 **A Predictive Model for Pathologic Complete Response in Breast Cancer Patients treated with Neoadjuvant Chemotherapy using Machine Learning** 248
 I. Kim, S.K. Kim, L. Seung Ah (South Korea)

EBCC-12 Scientific programme

Thursday 19 March 2020

Society Session: European Society of Surgical Oncology (ESSO) - Breast Cancer Surgery: Less is More - Simpler is Better

08:00 - 09:30 Picasso

Chair: Isabel T. Rubio (Spain)
 Chair: Tibor Kovacs (United Kingdom)

08:00 **Risks of overdoing in breast cancer**
 Speaker: Maria João Cardoso (Portugal)

08:18 **Q & A**

08:23 **Surgical management of local recurrences in breast cancer**
 Speaker: Oreste Gentilini (Italy)

08:41 **Q & A**

08:46 **Is overexploring and overtreating the axilla avoidable?**
 Speaker: Peter Dubsy (Switzerland)

09:04 **Q & A**

09:09 **Certification in breast surgical oncology and oncoplastics**
 Speaker: Tibor Kovacs (United Kingdom)

09:27 **Q & A**

Teaching Lecture: New Trends in Radiation Therapy


08:30 - 09:00 Goya

08:30 **New Trends in Radiation Therapy**
 Speaker: Charlotte E. Coles (United Kingdom)

Teaching Lecture: Counselling Healthy Carriers with High Moderate and low Penetrance Genes

09:00 - 09:30 Goya

09:00 **Counselling Healthy Carriers with High Moderate and low Penetrance Genes**
 Speaker: D.M. Eccles (United Kingdom)
Describe genetic landscape for inherited breast cancer risk
Explore different elements that contribute to risk perception
Describe approaches to risk stratified management



Teaching Lecture: Early Triple-ve

08:30 - 09:00

Miro

09:00 **Early Triple-ve**

Speaker: Alessandra Gennari (Italy)

Teaching Lecture: Early HER2+ve

09:00 - 09:30

Miro

09:00 **Early HER2+ve**

Speaker: Javier Cortés (Spain)

Clinical Science Symposium: Artificial Intelligence in Breast Cancer Care

10:00 - 11:30

Picasso

Chair: Maria João Cardoso (Portugal)

Chair: Paola Mosconi (Italy)

10:00 **Surgery**

Speaker: Maria João Cardoso (Portugal)

10:15 **Imaging**

Speaker: Ritse Mann (Netherlands)

10:30 **Pathology**

Speaker: Hugo Horlings (Netherlands)

10:45 **Implementation of clinical decision support systems for breast cancer treatment**

Speaker: Brigitte Seroussi (France)

11:00 **Patient perspective**

Speaker: Vesna Ramljak (Croatia)

11:15 **Challenges in implementing AI for population breast cancer screening**

Speaker: Nehmat Houssami (Australia)

Multidisciplinary Team in the Real World: Optimal Management of Brain Metastasis

10:00 - 11:00

Goya

Moderator: Volkmar Mueller (Germany)

Radiation oncologist


Panel: Barbara Jereczek (Italy)

Medical oncologist

Panel: Thomas Bachelot (France)

Neurosurgeon

Panel: Philippe Metellus (France)



Radiologist

Panel: Paolo Vitali (Italy)

Society Session: European Society of Breast Imaging (EUSOBI) - Case-Based Radiologic-Pathologic Correlation

10:00 - 11:30

Miro

Moderator: Karen Kinkel (Switzerland)

Moderator: Tibor Tot (Sweden)

DCIS

10:00 **Radiologist**

Speaker: F Pediconi (Italy)

1. To learn about different types of DCIS.

2. To become familiar with different imaging appearances of DCIS.

3. To appreciate radiologic-pathologic correlations.

10:15 **Pathologist**

Speaker: G D'Amati (Italy)

Learn about the gross and histologic features of DCIS

Learn about correlations between pathologic features and imaging

Be aware of potential pitfalls

10:30 **Discussion**

Neoadjuvant treatment response evaluation

10:45 **Radiologist**

Speaker: Julia Camps-Herrero (Spain)

11:00 **Pathologist**

Speaker: Laia Bernet Vegue (Spain)

11:15 **Discussion**

Debate: This House Supports Breast Cancer Screening Based on Population age Rather than Specific Risks

11:45 - 12:45

Picasso

Co-Moderator: Robert E. Mansel (United Kingdom)

Co-Moderator: Elizabeth Bergsten-Nordstrom (Sweden)

11:45 Speaker in favour: Jonas Bergh (Sweden)


12:00 Speaker against: Gareth Evans (United Kingdom)

12:15 Seconder in favour: David A. Cameron (United Kingdom)

12:25 Seconder against: Harry J. De Koning (Netherlands)

12:35 **Voting/Conclusion**

Best Practice Session: The Management of Young Patients



11:15 - 12:15

Dali

- Chair: Olivia Pagani (Switzerland)
 Chair: Tanja Spanic (Slovenia)
- 11:15 **Fertility**
 Expert: Matteo Lambertini (Italy)
- 11:25 **Pregnant patients**
 Expert: Sibylle Loibl (Germany)
- 11:35 **Endocrine therapy**
 Expert: Olivia Pagani (Switzerland)
Nurse (Panel member)
 Expert: Gillian Howard Jones (United Kingdom)
Patient (Panel member)
 Expert: Tanja Spanic (Slovenia)
- 11:45 **Panel discussion**

EUROPA DONNA Session: Strategies for women with MBC: What we are learning

11:45 - 12:45

Goya


- Chair: Karen Benn (Italy)
 Chair: Biljana Dodeva (Macedonia)
- 11:15 **Oncologist perspective/ABC alliance**
 Speaker: Fátima Cardoso (Portugal)
- 11:30 **New research on importance of exercise regime for women with MBC-PREFERABLE**
 Speaker: Anne May (Netherlands)
- 11:45 **European MBC advocacy education and surveys on return to work**
 Speaker: Karen Benn (Italy)
- 11:55 **National Programme Italy: FORTEMENTE - Psychological support for women with MBC**
 Speaker: Rosanna Fidanzia - D'Antona (Italy)
- 12:05 **Discussion**

Poster in the Spotlight: Poster in the Spotlight II

13:30 - 14:00

Poster Area/Exhibition Hall

- Mona to appoint PA as chair**
- PB-004 **Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases** 103
E. Laakmann, I. Witzel, T. Neunhöffer, R. Weide, M. Schmidt, T.W. Park-Simon, V. Möbus, C. Mundhenke, A. Polasik, K. Lübbe, T. Hesse, K. Riecke, M. Thill, P.A. Fasching, C. Denkert, T. Fehm, V. Nekljudova, J. Rey, S. Loibl, V. Müller (Germany)
- Moderated discussion**
- PB-005 **Real-world analysis of patients' clinical and geriatric characteristics aged ≥ 70 years with advanced breast cancer receiving palbociclib with endocrine therapy in the French cohort PALOMAGE** 104
E. Brain, J. Grosjean, M. Pulido, E. Paillaud, E. Carola, N. Jovenin, O. Guillem, M. Chehimi, W. Mina, P. Caillet, L. Tassy, C. Falandry, N. Rifi, J.M. Vauthier (France)



Moderated discussion

- PB-006 **Gut microbial short chain fatty acids are associated with pathological complete response (pCR) after neoadjuvant chemotherapy for breast cancer** 105
 K. Ross, R. Papadopoulou, B. Nichols, M. Macleod, J. Fraser, S. Barrett, J. Evans, K. Gerasimidis, I. Macpherson (United Kingdom)

Moderated discussion

Multidisciplinary Team in the Real World: Local Relapse After Breast Conservation

14:45 - 15:45 Dali

Moderator: Frederieke Van Duijnhoven (Netherlands)

Medical oncologist

Panel: Joana Ribeiro (Portugal)

Radiation oncologist

Panel: Icro Meattini (Italy)

Radiologist

Panel: Francesco Sardanelli (Italy)

Educational Session: Antibody Drug Conjugates: Optimising Drug Delivery

14:45 - 15:45 Goya

Chair: David A. Cameron (United Kingdom)

14:45 **Mechanisms of action of ADCs**
 Speaker: Matthias Peipp (Germany)

15:05 **ADCs - Targeting HER family**
 Speaker: Junji Tsurutani (Japan)

15:25 **Discussion**

Proffered Paper Session: Proffered Papers Session


14:45 - 15:45 Picasso

Chair: Javier Cortés (Spain)

Predictors of efficacy in patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2-ABC): subgroup analyses of PALOMA-3 9
 Oral Abstract SP: Hope Rugo (USA)

Chemoprevention for breast cancer: A survey of the views of Australian women and clinicians 10
 Oral Abstract SP: Courtney Macdonald (Australia)

Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers 11
 Oral Abstract SP: Josephine Lopes Cardozo (Belgium)



Young Investigators Session: Interactive Lecture on Publishing Your Research

14:45 - 15:45

Room 129-130

Information and interactive discussion under the guidance of two Editors from (breast) oncology journals on tips and tricks regarding how to get your paper published.

Moderator: Fátima Cardoso (Portugal)

Moderator: Suzette Delalogue (France)

Clinical Science Symposium: Preoperative Systemic Therapy: How do we Respond to the Response?

16:15 - 17:45

Picasso

Chair: Emiel J. T. Rutgers (Netherlands)

Chair: Susan Knox (Italy)

16:15 **Systemic therapy**

Speaker: Michael Untch (Germany)

neoadjuvant therapy

postneoadjuvant therapy

targeted therapy

16:30 **Surgery**

Speaker: Marie Jeanne Vrancken - Peeters (Netherlands)

16:45 **Radiation oncology**

Speaker: Philip Poortmans (Belgium)

17:00 **Pathology**

Speaker: Frédérique Penault-Llorca (France)

17:15 **Psychology**

Speaker: Luzia Travado (Portugal)

17:30 **Minimally Invasive Complete Response Assessment of the breast after neoadjuvant systemic therapy (MICRA trial): interim analysis of a multicenter observational cohort study** 12

Oral Abstract SP: F.H. Duijnhoven (Netherlands)

Clinical Science Symposium: Implants

16:15 - 17:45

Dali

Chair: Christoph Heitmann (Germany)

Chair: Nicole Zernik (France)

16:15 **Are they safe?**

Speaker: Frederieke Hagemann (Germany)

16:30 **When and where**


Speaker: Christoph Heitmann (Germany)

16:45 **Best imaging with implants**

Speaker: Eva Fallenberg (Germany)

17:00 **Radiation oncology**

Speaker: Orit Kaidar-Person (Israel)



- 17:15 **Pathology**
Speaker: Philippe Gaulard (France)
- 17:30 **Safety of pre-pectoral breast reconstruction followed by post mastectomy radiotherapy** 13
Oral Abstract SP: M. Bernini (Italy)

Society Session: EUSOMA - Breast Centres Certification (BCCERT) - Breast Centre: Challenges in Quality of Care

16:15 - 17:45 Goya

- Chair: Isabel T. Rubio (Spain)
- 16:15 **Evidence of the benefits of multidisciplinary approach in 2020**
Speaker: Luigi Cataliotti (Italy)
Improving Survival, Quality of Care, Quality of Life
- 16:35 **Updating in QIs trend**
Speaker: Antonio Ponti (Italy)
- 16:50 **Work in progress: Quality indicators in metastatic breast cancer care**
Speaker: Fátima Cardoso (Portugal)
- 17:05 **The requirements of a specialist Breast Centre: the new Eusoma document endorsed by ECCO and ESMO**
Speaker: Laura Biganzoli (Italy)
- Present requirements in offering quality of care to breast cancer patients
- Reinforce the concept of multidisciplinary
- Point out the importance of having patient-centered pathways that cover the entirety of the breast cancer course
- 17:20 **Clinical research in a Breast Centre**
Speaker: Olivia Pagani (Switzerland)
- 17:35 **Discussion**

Young Investigators Session: Lecture on Funding Your Research

16:15 - 17:00 Room 129-130

- Tips and tricks from a senior expert on where to look for funding, your application, etc. with a focus on smaller grants.**
- 16:15 **Requesting grants**
Speaker: Jelle Wesseling (Netherlands)
- 16:25 **Perspective of the grant selection committee**
Speaker: David A. Cameron (United Kingdom)
- Interactive Discussion**

Young Investigators Session: Basics of Statistics

17:00 - 18:00 Room 129-130

An educational session on the most important statistical principles that young investigators should know to be able to have a good critical view on the research presented at conferences and in papers

Moderator: Coralie Poncet (Belgium)

Topics

Trial phases and possible design (incl. discussion on randomization, blinding)

Choice of primary endpoint (incl. discussion on time to event endpoints, importance of schedule assessment, which endpoints are most clinically relevant; a significant p-value does perhaps not always mean a significant gain for a patient, eg. a 2 month difference; do we call this a success?)

Fundamentals on hypothesis testing (including discussion on type 1 error, power, clinical vs stats significance)

Ingredients of sample size calculation

Poster Session: Advanced Disease

Poster Area/Exhibition Hall

PB-007	<p>The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients</p> <p><u>R. Watanuki</u>, A. Shimomura, S. Yazaki, S. Narita, H. Okuma, T. Nishikawa, M. Tanioka, K. Sudo, T. Shimoi, E. Noguchi, Y. Kan, K. Tamura (Japan)</p>	249
PB-008	<p>An exploratory phase II study of Eribulin re-challenge after short term therapy of 5-fluorouracil for HER2-negative, advanced or recurrent breast cancer</p> <p><u>T. Takashima</u>, S. Nishimura, H. Kawajiri, Y. Mizuyama, T. Nishimori, S. Yamagata, S. Tokunaga, K. Tezuka, S. Tei, T. Sunami, K. Ikeda, Y. Ogawa, S. Kashiwagi, S. Noda, N. Onoda, T. Ishikawa, S. Kudoh, M. Takada, K. Hirakawa, M. Ohira (Japan)</p>	250
PB-009	<p>Characteristics of metastatic breast cancer patients obtaining a clinical complete response with systemic therapies</p> <p><u>Y. Horimoto</u>, R. Sasaki, K. Nakai, K. Iijima, M. Saito (Japan)</p>	251
PB-010	<p>Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: an exploratory cohort study</p> <p><u>G. Pelizzari</u>, E. Bertoli, D. Basile, M. Giavarra, L. Gerratana, M. Bartoletti, C. Lisanti, C. Corvaja, M.G. Vitale, A. Michelotti, D. Avoledo, L. Da Ros, M. Bonotto, S. Bolzonello, P. Di Nardo, G. Fasola, M. Mansutti, S. Spazzapan, A.M. Minisini, F. Puglisi (Italy)</p>	252
PB-011	<p>Does Neo-adjuvant chemotherapy response in the primary breast tumour correlate with axillary response in proven node positive ER positive HER2 negative disease?</p> <p><u>N. Borkar</u>, E. Provenzano, E. Garreffa, J. Benson, P. Forouhi, L. Hugh-Davies, C. Wilson, K. McAdam, S. Russell, A. Agrawal (India)</p>	253
PB-012	<p>Treatment with eribulin could suppress epithelial-mesenchymal transition (EMT) characteristics in tumors of patients with metastatic breast cancer</p> <p><u>T. Utsumi</u>, T. Hayashi, N. Kobayashi, M. Hikichi, K. Ushimado, S. Nakano, K. Fujii, T. Ando (Japan)</p>	254
PB-013	<p>Compared expression of Tumour Infiltrating Lymphocytes and FOXA1 in matched pairs of brain metastasis and primary breast cancer and prognostic implications – a pilot study</p> <p><u>A. Thulin</u>, E. Rönnerman, S. De Lara, C. Chamalidou, A. Schoenfeldt, A. Kovács, B. Linderholm (Sweden)</p>	255
PB-014	<p>Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer (ABC) in Asia and Middle East (ME): Results from the Count Us, Know Us, Join Us (CUKUU) survey</p> <p><u>A. Ripley</u>, J. Lehr, M. Shaalan, S. Koppikar, V. Gupta, M. Gao, N. Abdelbaky, F. Cardoso (USA)</p>	256

PB-015	Neutrophil to lymphocyte ratio (NLR) may predict survival and efficacy of eribulin in advanced breast cancer patients <u>Y. Haruyama</u> , E. Fukuma, O. Yu, Y. Koshida, N. Sakamoto, A. Gen, R. Nakagawa, M. Nashimoto, M. Sakamoto, K. Teraoka, M. Nakagawa (Japan)	257
PB-016	Use of indocyanine green (ICG) alone as a tracer for sentinel lymph node detection after neoadjuvant chemotherapy in breast cancer patients <u>F. Cattin, MD</u> , T. Fogacci, G. Frisoni, G. Semprini, L. Fabiocchi, D. Samorani (Italy)	258
PB-017	Breast cancer patients with leptomeningeal carcinomatosis: Treatment results and validation of prognostic indexes <u>I. Ratosá</u> , T. Znidaric (Slovenia)	259
PB-019	Treatment efficacy and predictors of durable response to capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort <u>S. Thijssen</u> , H. Wildiers, K. Punie, B. Beuselinck, P. Berteloot, S. Han, E. Van Nieuwenhuysen, T. Van Gorp, I. Vergote, P. Neven (Belgium)	261
PB-020	Cyclin-dependent kinase 4/6 inhibitors palbociclib or ribociclib combined with endocrine therapy and radiation therapy for patients with metastatic breast cancer <u>I. Ratosá</u> , E. Scoccimarro, L. Dominici, M. Orazem, M. Steinacher, M. Aquilano, C. Cerbai, I. Desideri, T. Marinko, L. Livi, I. Meattini (Slovenia)	262
PB-021	Real-World data of triplet combination of trastuzumab, lapatinib and chemotherapy in HER2-positive metastatic breast cancer: a multi-center retrospective study <u>Y. Li</u> , C. Gong, Q. Lu, Z. Zhou, T. Luo, W. Li, G. Li, R. Ge, B. Wang (China)	263
PB-022	Impact of Ki67 and progesterone receptor on PFS with cyclin-dependent kinase 4/6 inhibitors in HER2-negative advanced breast cancer: a real world mono-institutional experience <u>M. Palleschi</u> , E. Barzotti, E. Melegari, S. Manunta, F. Mannozi, A. Vagheggini, R. Maltoni, A. Fedeli, S. Sarti, L. Cecconetto, P. Possanzini, S. Ravaioli, M.M. Tumedei, D. Amadori, S. Bravaccini, A. Rocca (Italy)	264
PB-023	Improved QTcF diagnostic using tele-cardiology <u>L.S. Fink</u> , Y. Patel, T. Schinköthe (Germany)	265
PB-024	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the Ballet study <u>S. Corona</u> , F. Giudici, G. Jerusalem, E. Ciruelos, C. Strina, M. Sirico, O. Bernocchi, M. Milani, M. Dester, N. Ziglioli, G. Barbieri, V. Cervoni, F. Montemurro, D. Generali (Italy)	266
PB-025	HLX02, a China-manufactured Trastuzumab Biosimilar Versus EU-sourced Trastuzumab: Results of a Global Phase 3, Randomized, Double-blind Efficacy and Safety Comparative Study in Metastatic Breast Cancer <u>B. Xu</u> , Q. Zhang, T. Sun, W. Li, Y. Teng, X. Hu, I. Bondarenko, H. Adamchuk, Y. Li, B. Shan, J. Cheng, X. Wang, Y. Chen, W. Jiang, S. Liu, X. Zhang, E. Liu, A. Luk, Q. Wang (China)	267
PB-026	Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system M. Schmidt, T. Degenhardt, P.A. Fasching, D. Lüftner, V. Müller, C. Thomssen, C. Schem, I. Witzel, T. Decker, H. Tesch, S. Kümmel, C. Uleer, R. Würstlein, O. Hoffmann, M. Warm, N. Marschner, R.E. Kates, J. Schumacher, <u>N. Harbeck</u> (Germany)	268
PB-027	Time to first health care contact, referral pathways and stage at presentation – the experience from four South African breast units <u>C. Pothas</u> , S. Nietz, T. Oluwa, M. Witness, H. Cubasch, M. Joffe (South Africa)	269

Poster Session: Advocacy

Poster Area/Exhibition Hall

PB-028	Women's descriptions six months post notification of positive BRCA 1/2 genetic mutations <u>M. Becker</u> (USA)	270
--------	---	-----

PB-029	Breast cancer community screening in low resource settings: lessons from Pune, India <u>L. Busheri</u> (India)	271
PB-030	Patient-informed learning to assist development of personalised treatment care plans for breast cancer patients and survivors <u>C. Kearns</u> , A. Burke, W.M. Gallagher, C.M. Kelly (Ireland)	272
PB-031	How I survived breast cancer 3 times and why I support the unique BRESO project <u>S. Bianca</u> (Italy)	273
PB-032	Unintended bias in clinical trials: the prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials <u>M.K. Abel</u> , I. Diaz, J. Levine, L. Pate, E. Viggiano, M. Melisko, R. Mukhtar (USA)	274

Poster Session: Basic Science and Translational Research

Poster Area/Exhibition Hall

PB-033	Interplay between the Pan-Tumor Suppressor miR-939-5p and the oncogenic lncRNA-HEIH dually curbs Hydrogen Sulphide and Nitric Oxide production in breast cancer cells <u>H. Nafea</u> , R. Youness, K. Abou-Aisha, M. Gad (Egypt)	275
PB-035	miR-486-5p and miR-17-5p: Novel Immunomodulatory Non-coding RNAs Drawn Downstream 3'-O-Acetylviitexin in Triple Negative Breast Cancer <u>A. Elkhoully</u> , R. Youness, A. Abdelmotaal, M. Gad (Egypt)	277
PB-036	Methylation of the NT5E gene, encoding for CD73: prognostic significance in breast cancer <u>Y.J. Jeong</u> , H.K. Oh, H.R. Choi, S.H. Park (South Korea)	278
PB-037	impact of CDK4 knock out using CRISPR/Cas9 gene editing technology on breast cancer progression <u>A. Ahmed</u> , D. Ashraf, A. Bahaa, H. El-Tayebi, H. Adwan (Egypt)	279
PB-038	Inverse association between IFN-γ level released from NK cell and breast cancer stage <u>J.I. Kim</u> , E. Um (South Korea)	280
PB-039	Multi-targeting antibody to control proliferation, metastasis and angiogenesis in mammary gland tumor <u>R. Vafaei</u> , S. Moradi, M.R. Esmailnejad, M. Salehi, N. Jalili, K. Barzaman, L. Farahmand (Iran)	281
PB-040	Computerized scoring tool for identification and quantification of different immune cell populations in breast tumor regions <u>L. Berben</u> , H. Wildiers, C. Kenis, B. Dalmasso, A. Smeets, H. Vos, P. Neven, L. Marcelis, A. Antoranz Martinez, F. Bosisio, G. Floris, S. Hatse (Belgium)	282
PB-041	Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information <u>C.A. Frisell</u> , J. Lagergren, M. Halle, J. De Boniface (Sweden)	283
PB-042	Socioeconomic status influences immediate breast reconstruction rates, patient information and involvement in surgical decision-making <u>C.A. Frisell</u> , J. Lagergren, M. Halle, J. De Boniface (Sweden)	284
PB-043	Evaluation of circulating cell-free DNA and its integrity as a potential predictive biomarker of breast cancer onset: a pilot study <u>B. Scaggiante</u> , F. Giudici, F. Zanconati, C. Bottin, C. Revoltella, S. Corona, M. Cappelletti, D. Generali, M. Bortul (Italy)	285
PB-044	PIK3CA mutations and predicting the therapeutic effects of neoadjuvant chemotherapy in primary breast cancer <u>A. Sato</u> , M. Tanabe, Y. Tsuboi, Y. Ito, F. Akiyama, S. Takahashi, Y. Murakami, Y. Seto (Japan)	286

PB-045	Project PRIMO – Combining Patient Derived Breast Cancer Microtumors and DigiWest protein signaling pathway profiling for therapeutic response prediction <u>N. Anderle</u> , F. Ruoff, A. Koch, A. Hartkopf, S. Brucker, M. Templin, C. Schmees (Germany)	287
PB-046	Verification of metabolic competition mechanisms in androgen receptor-positive triple negative breast cancer <u>Y. Asano</u> , S. Kashiwagi, R. Kouhashi, A. Yabumoto, S. Ishihara, Y. Tauchi, T. Morisaki, S. Noda, T. Takashima, N. Onoda, H. Kosei, M. Ohira (Japan)	288
PB-047	Clinical correlation between Programmed Cell Death Ligand One (PD L-1) Expression, Tumor Infiltrating Lymphocytes (TILs) and pathological response of locally advanced Human Epidermal Receptor (HER 2) & Triple Negative (TN) Breast Cancer (BC) Egyptian patients undergoing neoadjuvant Therapy <u>E. Shash</u> , E. Khorshed, A. Namour, E. El Desouky, A. Bahnassy, N.M.A. Allahloubi (Egypt)	289
PB-048	Plasma markers showing differential baseline expression in relapsing versus non-relapsing patients with hormone sensitive breast tumors <u>S. Hatse</u> , Y. Lambrechts, K. Punie, G. Floris, L. Berben, A. Laenen, D. Lambrechts, C. Desmedt, C. Weltens, A. Smeets, C. Van Ongeval, P. Neven, H. Wildiers (Belgium)	290
PB-049	The value of uPA and PAI-1 levels in triple negative breast cancer <u>M. Sobocan</u> , Z. Ledinek, B. Crnobrnja, N. Čas Sikošek, N. Fokter Dovnik, R. Kavalar, J. Knez, I. Takač (Slovenia)	291
PB-050	Integration of genomic profiling and functional screening identifies potential driver somatic copy number alterations in triple-negative breast cancer <u>G. Xie</u> , X. Xu (China)	292
PB-052	Patient-assisted vs standard compression mode in mammography screening: A randomized clinical trial E.N. Arenas Rivera, M. Posso, <u>M. Pitarch</u> , P. Nicolau Batalla, M.D.M. Vernet, R. Alcantara Souza (Spain)	294
PB-053	Prognostic utility of androgen receptor signaling pathway in invasive breast cancer <u>S. Kurozumi</u> , A. Katayama, T. Fujii, M. Endo, E. Nishiki, S. Tokuda, Y. Nakazawa, S. Obayashi, R. Yajima, S. Shiino, J. Horiguchi, N. Mongan, T. Oyama, E. Rakha, K. Shirabe (Japan)	295
PB-054	Axillary lymph node involvement may be predicted by breast cancer subtype: a single center experience. <u>G. Cisternino</u> , G. Dajti, A. Pellegrini, M. Serra, S. Zanotti, C. Ceccarelli, D. Santini, M. Taffurelli (Italy)	296
PB-055	Micro-morphological regression patterns of tumors and lymph nodes following neoadjuvant chemotherapy for breast cancer with follow-up analysis: a new scoring system with implication into practice <u>M. Śniadecki</u> , M. Orłowska-Volk, T. Erbes, E. Wycinka, M. Werner (Germany)	297
PB-056	Relationship between VEGF-A and PD-L1 expression in primary breast cancer <u>E. Nishiki</u> , T. Hirakata, M. Endo, S. Tokuda, Y. Nakazawa, S. Kurozumi, S. Obayashi, R. Yajima, A. Katayama, T. Oyama, T. Fujii (Japan)	298
PB-057	Molecular subtypes and outcomes of different breast cancer histologies <u>E. Beh</u> , A. Raman, R.Y.C. Tan, W.S. Ong, V. Tan, J. Iqbal, F.Y. Wong, Y.S. Yap (Singapore)	299
PB-058	Pre-clinical and clinical development of lead molecule (IM522) against Paclitaxel non-responsive TN Breast Cancers <u>F. Malik</u> (India)	300
PB-059	Gene expression profiles in premenopausal women with HR+ HER2- early breast cancer <u>H. Ni</u> , A. Kurt, J. Kumbrink, A. Seiler, D. Mayr, T. Degenhardt, F. Hagemann, R. Würstlein, N. Harbeck, T. Eggersmann (Germany)	301
PB-060	Circulating tumor associated cells in breast cancers are resistance educated towards prior anthracycline treatments. <u>A. Srinivasan</u> , D. Akolkar, D. Patil, S. Limaye, R. Page, A. Ranade, R. Patil, V. Datta, S. Patil, V. Mhase, S. Apurwa, S. Pawar, R. Datar (India)	302
PB-061	Real-time non-invasive chemoresistance profiling of circulating tumor associated cells in breast cancers to determine resistance towards mitotic inhibitors .	303

	<u>A. Srinivasan</u> , D. Akolkar, D. Patil, S. Limaye, R. Page, A. Ranade, R. Patil, S. Patil, V. Mhase, V. Datta, S. Apurwa, S. Pawar, R. Datar (India)	
PB-062	BRCA variant classification of ClinVar submitter content from ENIGMA, ARUP laboratories and German cancer consortium compared to MH BRCA® and correlation with response to PARP inhibition in MH GUIDE®	304
	K. Stecker, <u>U. Schmidt-Edelkraut</u> , J. El Hokayem, M. Hartenfeller, F. Diella, M. Stein, J. Hermanns, T. Holtrup, S. Hettich, T. Soldatos, D. Jackson, S. Brock, C. Meisel (Germany)	
PB-063	Interaction of PAFAH and beta-catenin in BRCA1 mutant breast cancer	305
	Y. Liao, D. Mayr, E. Schmoeckel, A. Hester, T. Kolben, C. Zeder-Göß, R. Würstlein, N. Harbeck, S. Mahner, U. Jeschke, F. Trillsch, <u>B. Czogalla</u> (Germany)	
PB-064	A Breast 3D model as a possible tool for non-invasive tumour localization in breast surgery	306
	<u>P. Gouveia</u> , S. Bessa, H. Oliveira, E. Batista, M. Aleluia, J. Ip, J. Costa, L. Nuno, D. Pinto, C. Mavioso, J. Anacleto, N. Abreu, P. Morgado, M. Martinho, J. Teixeira, P. Carvalho, J. Cardoso, C. Alves, F. Cardoso, M. João Cardoso (Portugal)	
PB-065	Application of culture-based assays to human malignant breast tissue can infer tumour microbiota composition	307
	G. Hogan, E. Rettedal, C. Murphy, <u>N. Narayanan</u> , D. O'Hanlon, M. Tangney, M. Corrigan (Ireland)	

Poster Session: Genetics

Poster Area/Exhibition Hall

PB-066	Characterization of 331G/A polymorphism of rp gene and identification of viral oncogene hmtv virus as genetic markers for the improvement of breast cancer management in Cameroon	308
	<u>N. Nguedia Kaze</u> (Cameroon)	
PB-067	circRNA Expression in serum exosome in breast cancer	309
	<u>S. Kolahdouzan</u> (Iran)	
PB-068	Non-BRCA hereditary gene mutations in the Mongol breast cancer patients of Russia	310
	<u>P. Gervas</u> , E. Denisov, A. Kiselev, A. Molokov, A. Ivanova, E. Choyznov, N. Cherdyntseva (Russian Federation)	
PB-069	Association of germline genetic variants with breast cancer survival in patient subgroups defined by standard clinic-pathological variables	311
	<u>A. Morra</u> , M. Escala-Garcia, S. Canisius, R. Keeman, M. Garcia-Closas, P.D.P. Pharoah, M.K. Schmidt (Netherlands)	
PB-070	Rates of contralateral breast cancer amongst patients with non-BRCA germline mutations	312
	<u>B. Murphy</u> , P. Nobecourt, M. Yi, B. Arun, A. Gutierrez, I. Bedrosian (USA)	
PB-071	Clinical outcomes according to BRCA status in breast cancer patients: could the BRCA mutation be used as a prognostic factor?	313
	<u>N. Park</u> , J.E. Lee, Z. Kim, S.M. Hur (South Korea)	
PB-072	Prevalence of germline BRCA pathogenic variants in a monoinstitutional cohort of patients with triple negative breast cancer	314
	<u>E. De Matteis</u> , M. Ciccarese, G. Ronzino, R. Forcignanò, V.E. Chiuri, G. Cairo, I. Bovenga, E. Spro, M.R. De Giorgio, P. Tarantino, L. Palma, S. Mauro, S. Leo (Italy)	
PB-073	Clinical pathological association with breast cancer gene analysis through next generation sequencing	315
	S. Jung, <u>C.W. Jeon</u> , J. Choi, D. Hyun, H. Lee, K. Kwon, H. Yoon (South Korea)	
PB-074	New germline RAD51D gene variant in the Mongol breast cancer patients	316
	<u>A. Molokov</u> , P. Gervas, N. Cherdyntseva (Russian Federation)	
PB-075	Use of multi gene- panel testing to detect hereditary breast cancer gene variants in patients attending to a breast cancer clinic, Peradeniya, Sri Lanka	317
	<u>L. Yatawara</u> , D. Jayasooriya, G. Hettiarachchi, B. Hewavithana (Sri Lanka)	

- PB-076 **The risk of colorectal cancer associated with BRCA 1 and/or BRCA 2 mutation carriers: systematic review and meta-analysis** 318
C. Cullinane, B. Creavin, E. O'Connell, L. Kelly, M.J. O'Sullivan, M.A. Corrigan, H.P. Redmond (Ireland)
- PB-077 **BRCA screening among Jewish community of Rome** 319
L. De Marchis, A. Minucci, A. Gelibter, G. Mazzuccato, V. Magri, G. Moscati, R. Madaio, P. Marchetti, A. Urbani, E. Cortesi, E. Capoluongo (Italy)

Poster Session: Lifestyle, Prevention including Secondary Prevention

Poster Area/Exhibition Hall

-
- PB-078 **Five-year follow-up results of aerobic and circuit training on bone mineral density in early breast cancer patients** 320
C. Blomqvist, L. Vehmanen, H. Sievänen, P. Kellokumpu-Lehtinen, R. Nikander, R. Huovinen, H. Penttinen, M. Utriainen, K. Tokola, T. Saarto (Finland)
- PB-079 **Age-, community-matched Body Mass Index and overall survival in patients with breast cancers** 321
J. Lee, S. Park, M. Oh (South Korea)
- PB-080 **An audit of chemoprevention provision in a breast cancer family history clinic** 322
A. Patel, K. Foster (United Kingdom)
- PB-081 **Is socioeconomic status a barrier for individual breast cancer awareness in developing countries ?** 323
A. Giri Sarkar (India)
- PB-082 **Getting fit for surgery: introducing a multi-modal prehabilitation programme for our breast surgical patients** 324
F. Wu, R. Laza-Cagagias, A. Pagarkar, M. El Gammal, T. Rampal (United Kingdom)
- PB-083 **The effects of lifestyle modification, including dietary and physical activity interventions, on Anthropometric indices and Quality of life of patients with breast cancer: A systematic review and meta-analysis of clinical trials** 325
E. Razmpoosh, A. Sajadian, S. Vafa, M. Zarrati, M. Raji, A. Salehi-Abargouei (Iran)
- PB-084 **Muscle quality is a prognostic factor for postoperative complications after DIEP-flap breast reconstruction** 326
N. Sadok, H. Michelle, A. Viddeleer, J. Klaase, P. Werker, G. De Bock, L. Jansen(Netherlands)
- PB-085 **Estimating lung cancer and cardiovascular mortality in female breast cancer patients receiving radiotherapy.** 327
T. Mulliez, K. Barbé, M. De Ridder (Belgium)
- PB-086 **Quality of life (QoL) post surgical treatment of breast carcinoma: a prospective study** 328
E. Palma, G. Rizzo, S. Papi, F. Combi, S. Fenocchi, G. Tazzioli, R. Massa (Italy)

Poster Session: Local Regional Treatment - Radiotherapy

Poster Area/Exhibition Hall

-
- PB-087 **Hypofractionated boost to the tumor bed in early breast cancer: Skin toxicity analysis** 329
G. Oses, T.D. Barreto, C. Cases, C. Castro, A. Lloret, J. Saéz, M. Mollà (Spain)
- PB-088 **Exposure of the oesophagus in breast cancer radiotherapy: a systematic review of oesophageal doses published 2013-2018** 330
F. Duane, A. Kerr, M. Aznar, Z. Wang, C. Taylor (Ireland)

PB-089	Chronic toxicity after intraoperative electron radiotherapy as boost followed by whole breast irradiation G. Oses, <u>M. Mollà</u> , I. Alonso, X. Caparros (Spain)	331
PB-091	Central review of radiation therapy planning among patients (pts) with breast-conserving surgery (BCS): results from a quality assurance process integrated into the INSEMA trial <u>G. Hildebrandt</u> , A. Stachs, B. Gerber, J. Potenberg, D. Krug, K. Wolter, T. Kühn, T. Müller, F. Sedlmayer, J. Kaiser, R. Reitsamer, J. Heil, M. Hahn, V. Nekljudova, I. Bekes, S. Loibl, T. Reimer (Germany)	333
PB-092	Early invasive ductal breast cancer: review after 5-year median follow-up of the first 681 patients treated by partial breast irradiation with intraoperative electron radiation therapy <u>C. Philippson</u> , S. Simon, C. Vandekerkhove, I. Veys, D. Noterman, F. De Neubourg, M. Roman, J.M. Nogaret, D. Larsimont, A. Desmet (Belgium)	334
PB-093	The effect of a decision aid for breast cancer patients deciding on their radiation treatment <u>D. Raphael</u> , N. Russell, T. Van der Weijden, L. Boersma (Netherlands)	335
PB-094	Resource to prepare patients for deep inspiration breath hold: The RESPIRE project H. Probst, J. Barry, H. Clough, M. Lindley, M. Russel, R. Keeley, J. Ulman, J. Willis, <u>M. Burton</u> (United Kingdom)	336
PB-095	Results of locoregional radiotherapy or axillary dissection in breast cancer with pN0(i+) and pN1mi nodal disease <u>A. Altinok</u> , F. Tokat, N. Bese, U. Ince, C. Uras (Turkey)	337
PB-096	Prospectively registered acute toxicity in breast cancer patients undergoing adjuvant intensity modulated proton therapy <u>K. Verhoeven</u> , T. Opbroek, G. Vilches-Freixas, K. Limpens, J. Mannens, M. Pijls, K. Van der Klugt, M. Velders, F. Visser, S. Peeters, B. Reymen, A. Van Baardwijk, J. Van Loon, G. Bosmans, L. Boersma (Netherlands)	338

Poster Session: Optimal Diagnosis

Poster Area/Exhibition Hall

PB-097	Magnetic resonance imaging: role in the response to neoadjuvant therapy of breast cancer <u>A. Surace</u> , G. Pasquero, C. Marengo, G. Menato, A. Ponti, M. Bortolini, V. Marra, M.P. Mano, M.G. Baù (Italy)	339
PB-098	Deep learning enables fully automated mitotic density assessment in breast cancer histopathology <u>M. Balkenhol, MD</u> , P. Bult, D. Tellez, W. Vreuls, P. Clahsen, F. Ciompi, J. Van der Laak (Netherlands)	340
PB-099	Prone, stereotactic, vacuum-assisted breast biopsy <u>M. Dr. Cs. Jánvári</u> , G. Forrai, E. Riedl (Hungary)	341
PB-100	Same day estrogen, progesterone and HER2neu receptor assessment in breast cancer diagnosis using Core Wash Cytology <u>R.C. Van Den Oudenalder</u> , J. Bulte, L. Strobbe, W. Vreuls (Netherlands)	342
PB-101	The relative eosinophil count in breast cancer as an emerging prognostic biomarker <u>C.E. Onesti</u> , C. Josse, B. Beaumecker, D. Boulet, J. Thiry, V. Bours, G. Jerusalem (Belgium)	343
PB-102	Diagnostic work-up in women suspect for breast cancer in the Netherlands <u>S. Siesling</u> , M. Voets, K. Groothuis, L. Veneklaas, S. Manohar, M. Brinkhuis, J. Veltman, L. De Munck, L.F. De Geus-Oei, M. Broeders (Netherlands)	344
PB-103	Is sentinel lymph node biopsy necessary in the setting of microinvasive DCIS? <u>K. Desai</u> , R. Pham, J. Shin, K. Horn, A. Harbhajanka, L. Sieck (USA)	345

PB-104	Comparison of Breast Cancer Subtype Classification using Xpert® Breast Cancer STRAT4 Assay and Immunohistochemistry in 100 patients with Primary Breast Cancer <u>S. Janeva</u> , T. Parris, S. Nasic, S. De Lara, K. Larsson, R.A. Audisio, R. Olofsson Bagge, A. Kovács (Sweden)	346
PB-105	Reconsidering the management of palpable DCIS: a single institution audit N. Nair, <u>K. Kirti</u> , T. Shet, R. Hawaldar, V. Parmar, S. Gulia, S. Joshi, S. Murali, V. Vanmali, B. Bandare, S. Gupta, R. Badwe (India)	347
PB-106	Evaluation of FES (16α-[18F]-fluoro-17β-estradiol) PET for (re)staging of patients with clinical (locally) advanced or locoregional recurrent estrogen receptor positive breast cancer <u>R. Iqbal</u> , C. Mo, M.C.F. Cysouw, A.W.J.M. Glaudemans, G.A.P. Hospers, C.P. Schroder, C.C.M. Venema, C.W. Menke-van der Houven van Oordt (Netherlands)	348
PB-107	MRI accuracy in each immunophenotype to evaluate axillary tumour load after neoadjuvant treatment <u>M. Vernet-Tomas</u> , S. Perera, J. Castellà, B. Fabregó, N. Argudo, M. Jiménez, M. Segura, R. Alcantara, M. Pitarch, N. Arenas, F. Plancarte, I. Vázquez, L. Comerma, P. Nicolau (Spain)	349
PB-108	Digital breast tomosynthesis in the practice on the Clinic of Radiology - retrospective study <u>J. Slobodnikova, Doc.- CSc.</u> , V. Melus, K. Kaslikova, Z. Krajcovicova (Slovak Republic)	350
PB-109	External validation of the Swedish SUS nomogram in 2939 breast cancer patients to predict disease-free axilla in primary breast cancer <u>L. Dihge</u> , S. Majid, P.O. Bendahl, L. Huss, J. Manjer, L. Rydén (Sweden)	351
PB-110	Development of a qPCR based ER signaling pathway activity test predictive for response to endocrine therapy in ER IHC positive breast cancer patients <u>A. Pierik</u> , M. Akse, H. Van Zon, A. Van Brussel, M.A. Inda, Y. Wesseling-Rozendaal, H. Van Ooijen, W. Verhaegh, E. Den Biezen-Timmermans (Netherlands)	352
PB-111	Prognostic factors and patterns of recurrence of early mucinous breast cancers <u>A. Raman</u> , E. Beh, R.Y.C. Tan, W.S. Ong, V. Tan, I. Jabed, F.Y. Wong, Y.S. Yap (Singapore)	353
PB-112	Enhanced axillary assessment using contrast enhanced ultrasound (CEUS) before neo-adjuvant systemic therapy (NACT) in breast cancer patients identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant <u>K. Cox</u> , N. Dineen, J. Weeks, D. Allen, D. Akolekar, R. Chalmers, R. Burcombe, R. Jyothirmayi, C. Abson (United Kingdom)	354
PB-113	More precise mitotic count and estrogen/progesteron (ER/PR) scoring system impact on grading in pre- and post-neoadjuvant primary breast cancer: morphological, clinical and radiological assessment. <u>C. Giacometti</u> , M. Beda, A. Bellan, L. Vidotto, S. Ghiretti, L. Poletto, D. Pizzato, M. Maino, S. Duodeci, S. Zanolello, T. Mancuso, P. Bianchi, M. Cassaro (Italy)	355

Poster Session: Rehabilitation/Survivorship

Poster Area/Exhibition Hall

PB-115	Scalp cooling system to prevent alopecia: effectiveness, psychological effects and feasibility A. Guglielmi, E. Durizzotto, S. Bradaschia, B. Marzocchini, M. Malagoli, M. Ramella, F. Zanonati, M. Bortul, B. Scaggiante, <u>F. Giudici</u> , L. Dudine (Italy)	357
PB-116	Patient-reported outcome measures used for reporting late effects in postmenopausal breast cancer survivors and compared to general symptoms in a danish female age matched population <u>A.W.M. Nielsen</u> , M.H. Kristensen, B.V. Offersen, J. Alsner, R. Zachariae, H.M. Nielsen (Denmark)	358
PB-117	Evaluation of the use of primary and hospital care in long-term breast cancer survivors: a longitudinal study based on real-world data	359

	<u>A. Jansana</u> , M.I. Del Cura, T. Sanz, B. Poblador, M. Padilla, L. Domingo, C. Merce, A. Prados-Torres, B. Ibañez, I. Tamayo, A. Gimeno, M. Redondo, X. Castells, M. Sala (Spain)	
PB-118	Mobile health (mhealth) to improve quality of life in breast cancer survivors: study protocol for randomized controlled trial	360
	<u>M. Kaur</u> , B.S. Yadav, D. Dahiya, A. Akhilesh, S. Kaur, G. S, S. Ghai, (India)	
PB-119	Preoperative systemic treatment in breast cancer patients. Does the site of response matter?	361
	<u>A. Esqueva</u> , C. Siso, I. Miranda, C. Sobrido, M. Espinosa, R. Isabel (Spain)	
PB-120	Use of oral complementary-alternative medicine (OCAM) and fatigue among early breast cancer (BC) patients (pts)	362
	<u>N. Djehal</u> , J. Havas, A. Gbenou, E. Martin, C. Charles, S. Dauchy, B. Pistilli, C. Cadeau, P. Arveux, S. Everhard, J. Lemonnier, C. Coutant, P. Cottu, A. Lesur, G. Menvielle, A. Dumas, F. Andre, S. Michiels, I. Vaz-Luis, A. Di Meglio (France)	
PB-121	What signals cancer survivorship when revealed during the job application process to employers?	363
	<u>A. Sharipova</u> , S. Baert (Belgium)	

Poster Session: Risk Factors

Poster Area/Exhibition Hall


PB-122	Methylation of Glutathione-S-Transferase P1 Promoter in Egyptian females with breast cancer	364
	<u>M. Eldeeb</u> , T. Moghazy, H. Elattar, A. Farouk, R. Rashad (Egypt)	
PB-123	Methylene Tetrahydrofolate Reductase gene (C677T) polymorphism and serum folate level as risk factors of breast cancer among Egyptian females	365
	<u>M. Eldeeb</u> , T. Moghazy, G. Khalil, H. Elsheredy (Egypt)	
PB-125	The REMAR (Rhein-Main-Registry)-Study: Prospective evaluation of oncotype DX® Assay in Addition to Ki-67 for adjuvant treatment decisions in early breast cancer	367
	<u>M. Thill</u> , L. Anastasiadou, C. Solbach, V. Möbus, P. Baier, S. Ackermann, D. Giesecke, E. Schulmeyer, B. Gabriel, D. Mosch, S. Buchen, E. Krapfl, U. Hurst, M. Vescia, H. Tesch, S. Aulmann, C. Jackisch (Germany)	
PB-126	Association between tumor metabolism assessed by 18F-FDG PET-CT and molecular biological markers in luminal B type breast cancer	368
	<u>H.J. Lee</u> , H.S. Kim, W.Y. Kim, S.U. Woo, J.B. Lee (South Korea)	
PB-127	Change in trend in various clinic o-pathological factors and treatment profile of breast cancer patients in developing countries: a tertiary cancer center experience	369
	<u>S. Sharma</u> (India)	
PB-128	Implication of atypical supraclavicular F18-fluorodeoxyglucose uptake in patients with breast cancer: Relationship between brown adipose tissue and TILs, PD-L1	370
	<u>T. Fujii</u> , E. Nishiki, M. Endo, S. Tokuda, Y. Nakazawa, S. Kurozumi, S. Obayashi, R. Yajima, A. Katayama, T. Oyama (Japan)	
PB-129	Relationship between FDG uptake and platelet/lymphocyte ratio in patients with breast invasive ductal cancer	371
	<u>M. Endo</u> , E. Nishiki, S. Tokuda, Y. Nakazawa, S. Kurozumi, S. Obayashi, R. Yajima, T. Fujii (Japan)	
PB-130	Role of immunohistochemical determination of Bcl-2 and p53 expression in identifying hormone receptors positive/Her 2 negative (Luminal-like) high-risk breast cancer patients	372
	<u>G. Dajti</u> , G. Cisternino, M. Serra, A. Pellegrini, S. Zanotti, C. Ceccarelli, D. Santini, M. Taffurelli (Italy)	
PB-131	Evaluation of FISH of ER-positive breast cancer with low-HER2 expression could improve their survival.	373
	<u>T. Higuchi</u> , F. Arisawa, Y. Hayashi, I. Manabe, K. Suekuni, A. Adachi, T. Saito (Japan)	

PB-132	Does concomitant DCIS affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective	374
	<u>W.P. Lee</u> , S.S. Shetty, C.M.J. Seah, P.T. Tan, S.M. Tan (Singapore)	
PB-133	Breast cancer patients undergoing delayed deep inferior epigastric perforator (DIEP) flap reconstruction differ from their matched controls by a higher socioeconomic status and better overall survival	375
	<u>H. Adam</u> , A.C. Docherty Skogh, J. Frisell, J. De Boniface (Sweden)	
PB-134	Clinical prediction models for patients diagnosed with breast cancer: A systematic review	376
	T. Hueting, M. Van Maaren, H. Koffijberg, <u>S. Siesling</u> (Netherlands)	
PB-135	Circulating tumour DNA as a prognostic biomarker in predicting breast cancer outcomes: systematic review and meta-analysis	377
	<u>C. Cullinane</u> , F.H. Khawaja, D.P. O'Leary, L. Kelly, M.J. O'Sullivan, M.A. Corrigan, H.P. Redmond (Ireland)	
PB-135A	Factors affecting locoregional recurrence rate of breast conserving surgery in patients with neoadjuvant chemotherapy	377A
	<u>W.S. Chung</u> , H.H. Chou, W.L. Kuo, C.C. Yu, H.P. Tsai, S.C. Shen, C.H. Chu, Y.F. Lo, S.C. Chen (Taiwan)	

Poster Session: Screening

Poster Area/Exhibition Hall

PB-136	Evaluation of synthesized 2D mammography visibility with same pixel pitch as full-field digital mammography	378
	<u>Y. Furuya</u> , Y. Goto, K. Tsugawa, Y. Kanemaki (Japan)	
PB-138	Patterns of treatment and outcome of ductal carcinoma in situ for population-based screened women	380
	J. Luiten, E.J.T. Luiten, M.J.C. Van der Sangen, W. Vreuls, L.E.M. Duijm, V.C.G. Tjan-Heijnen, <u>A.C. Voogd</u> (Netherlands)	
PB-139	Feasibility and comparison study of augmented breast self examination vs. conventional breast self examination rural Indian women for early detection- results of POC study	381
	<u>N. Vaddeboina</u> , S. Attili, S. Peri, C. Sunkavalli, P. Dilip (India)	
PB-140	Breast Cancer Screening in undeveloped country. How precision medicine will help?	382
	<u>A. Fatima</u> (Pakistan)	
PB-141	Current status for breast density notification in Japan	383
	<u>H. Takahashi</u> , A. Matsumoto, H. Tsunoda, T. Uematsu, A. Suzuki, Y. Kasahara (Japan)	
PB-142	Patients' experience with mammography and attitude towards targeted breast ultrasound as initial imaging technique for the evaluation of focal breast complaints	384
	<u>C. Siebers</u> , L. Appelman, P. Appelman, S. Go, M. Van Oirsouw, M. Broeders, R. Mann (Netherlands)	
PB-143	Communication of biopsy results: a breast radiologist task?	385
	<u>V.A. Vitale</u> , F. Meani, M. Manganiello, C. Catanese, F. Del Grande, S. Rizzo (Switzerland)	
PB-144	Breast cancer risk assessment combined with a polygenic risk score in the general population for personalized screening	386
	<u>M. Saghatchian</u> , M. Abehsera, R. Sigal, E. Gauthier, T. Roirand, V. Helin, D. Gentien, L. Golmard, D. Stoppa-Lyonnet (France)	
PB-145	Cost-effectiveness of different digital mammography screening strategies in the Netherlands	387
	<u>L. Kregting</u> , V. Sankatsing, E. Heijnsdijk, N. Van Ravesteyn, H. De Koning (Netherlands)	
PB-146	Organisational characteristics of informed decision-making implementation in mammography screening programmes in 28 European countries	388
	<u>D. Ritchie</u> , G. Van Hal, S. Van Den Broucke (Belgium)	



- PB-147 **Breast Incidentalomas. How often do they are? – A 5-year Greek hospital experience** 389
 A. Mitrousias, P. Karathanasis, V. Kalles, M. Matiatou, G. Georgiou, E. Zografou, N. Michalopoulos, G. Zografos (Greece)
- PB-148 **YouTube as a source of information for breast-examination for patients and healthcare professionals: content, quality and reliability** 390
 K. Rangarajan, T. Chouari, M. Uhercik, H. Osman, R. Daoud, L. Iain, I. Karat (United Kingdom)

EBCC-12 Scientific programme

Friday 20 March 2020

Society Session: European Society for Radiotherapy & Oncology (ESTRO) - State of the Art in Radiation Oncology 2020

08:00 - 09:30

Goya

Chair: Dorota Gabrys (Poland)

Chair: Pedro C Lara (Spain)

08:00 **The best treatment in breast cancer radiotherapy 3D vs. IMRT**

Speaker: Icro Meattini (Italy)

08:20 **Is there is a place for SBRT in multiple metastases breast cancer?**

Speaker: Dorota Gabrys (Poland)

08:40 **Are there breast cancer patients for which radiotherapy can be safely omitted after BCT?**

Speaker: Philip Poortmans (Belgium)

09:00 **Opportunities and challenges of combining radiotherapy immunotherapy in breast cancer patients**

Speaker: Pedro C Lara (Spain)

09:20 **Q & A**


Teaching Lecture: Nipple Sparing Mastectomy: Indications and Pitfalls

08:30 - 09:00

Picasso

08:30 **Nipple Sparing Mastectomy: Indications and Pitfalls**

Speaker: Oreste Gentilini (Italy)



Teaching Lecture: Big Data: Help or Hindrance?

08:30 - 09:00

Dali

08:30 **Big Data: Help or Hindrance?**
Speaker: Fabrice André (France)

Teaching Lecture: Management of Low Risk DCIS

09:00 - 09:30

Picasso

08:30 **Management of Low Risk DCIS**
Speaker: Jelle Wesseling (Netherlands)

Teaching Lecture: How to Manage Pain in Post-Surgical and Metastatic Settings

09:00 - 09:30

Dali

09:00 **How to Manage Pain in Post-Surgical and Metastatic Settings**
Speaker: Nathan I. Cherny (Israel)

Clinical Science Symposium: Immuno-oncology in Breast Cancer


10:00 - 10:45

Picasso

Chair: G. Viale (Italy)

Chair: Tanja Spanic (Slovenia)

10:00 **Pathology**
Speaker: Roberto Salgado (Belgium)



10:15 **Systemic therapy**
Speaker: Carmen Criscitiello (Italy)

10:30 **Side effects**
Speaker: A. Varga (France)

Proffered Paper Session: Are your breasts still at risk?

10:45 - 11:30 Picasso

Chair: Eva Schumacher-Wulf (Germany)

10:45 **Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years** 14
Oral Abstract SP: Maartje Van Seijen (Netherlands)

10:55 **Differences in breast cancer risk after a benign breast disease according to the screening type** 15
Oral Abstract SP: Marta Roman (Spain)

11:05 **Contralateral breast cancer in patients with ductal carcinoma in situ and invasive breast cancer in the Netherlands** 16
Oral Abstract SP: Daniele Giardiello (Netherlands)

11:15 Discussant: Peter Dubsy (Switzerland)

Clinical Science Symposium: Early Breast Cancer and Germline Gene Panel Results: Help!

10:00 - 11:45 Dali


Chair: Gareth Evans (United Kingdom)

Chair: Marjanka K. Schmidt (Netherlands)

10:00 **Imaging**
Speaker: Rubina M. Trimboli (Italy)

10:15 **Gene panel testing for breast cancer: the geneticists viewpoint**
Speaker: Gareth Evans (United Kingdom)

1. What is the added value of testing for additional breast cancer genes beyond BRCA1/2?
2. What definition is there for an actionable breast cancer gene?
3. Are their specific categories of breast cancer (age, pathology, family history) that predicts higher rates of additional genes?




- 10:30 **Surgeon**
Speaker: Nina Ditsch (Germany)
- 10:45 **Medical oncologist**
Speaker: Shani Paluch-Shimon (Israel)
- 11:00 **Nurse/Psychologist**
Speaker: Anne Bredart (France)
- 3 Key objectives:*
 * To assess psychosocial difficulties and needs in women undergoing breast cancer genetic risk testing in genetics clinics in France, Germany and Spain
 * To test the effect of genetic risk communication in women undergoing breast cancer genetic risk testing in genetics clinics in France, Germany and Spain
 * To assess coping strategies in relation to genetic-specific psychosocial difficulties in order to target psychological intervention
- 11:15 **Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients – results from the REQUITE cohort study** 17
 Oral Abstract SP: Tim Rattay (United Kingdom)
- 11:30 **Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer.** 18
 Oral Abstract SP: Annette Lebeau (Germany)

Clinical Science Symposium: Advances in Imaging

10:00 - 11:30 Goya

- Chair: Geraldine Gebhart (Belgium)
- Chair: Francesco Sardanelli (Italy)
- 10:00 **PET/CT imaging**
Speaker: Geraldine Gebhart (Belgium)
- 10:15 **Molecular imaging (novel tracers)**
Speaker: Carolina Schröder (Netherlands)
- 10:30 **Breast imaging**
Speaker: Katja Pinker-Domenig (Austria)
- Know the currently available and emerging advanced breast imaging modalities
 Recognize the principle of digital breast tomosynthesis, contrast-enhanced mammography, multiparametric MRI and PET/MRI
 Identify the individual potential and challenges of each technique*
- 10:45 **Determinants of mammographic density change** 19
 Oral Abstract SP: Shadi Azam (Sweden)



11:00 **Radiomics and Machine Learning with DWI for breast cancer diagnosis: comparison with dynamic contrast enhanced and multiparametric MRI** 20
 Oral Abstract SP: Katja Pinker-Domenig (Austria)

Debate: This House Believes That all Node Positive Patients Need Post Mastectomy Radiation

11:45 - 12:45 Picasso

Moderator: Emiel J. T. Rutgers (Netherlands)

11:45 Speaker in favour: Birgitte Offersen (Denmark)

12:00 Speaker against: Mike Dixon (United Kingdom)

1. *Understand that many mastectomies are avoidable - best way to stop mastectomy and irradiation is to avoid mastectomy.*
2. *Appreciate that there is significant morbidity associated with post mastectomy radiotherapy particularly in patients undergoing breast reconstruction.*
3. *Be aware that many of the studies of post mastectomy radiotherapy were performed before the modern era of chemotherapy +/- antiHER2 agents and that local recurrence rates after mastectomy are reducing.*

12:15 Seconder in favour: Philip Poortmans (Belgium)

12:25 Seconder against: Christoph Thomssen (Germany)

12:35 **Voting/Conclusion**

Best Practice Session: The Management of Metastatic Elderly Patient

11:45 - 12:45 Dali


Chair: M. Aapro (Switzerland)

11:45 **Assessment**
 Expert: Hans Wildiers (Belgium)

- *explain how to assess older patients with cancer concerning their general health status (a process called geriatric assessment)*
- *explain why such an assessment is important*

11:55 **Unfit patient**
 Expert: Laura Biganzoli (Italy)

1. *Provide a definition of the UNFIT patient*



2. Identify the challenges related to the treatment of unfit patients
3. Report available data related to their treatment

12:05 **Fit patient**

Expert: Etienne Brain (France)

Nurse (Panel member)

Expert: Eva Gustafsson (Sweden)

Patient (Panel member)

Expert: Ellen Verschuur (Netherlands)

12:15 **Panel discussion**

EUROPA DONNA Session: ECIBC (European Commission Initiative on Breast Cancer) Implementation Plans

11:45 - 12:45

Goya

11:45 **Introduction: ECIBC and patient advocacy**

Co-Chair: Susan Knox (Italy)

11:52 **Overview of ECIBC**

Co-Chair: Annett Janusch Roi (Belgium)

12:00 **European breast cancer guidelines**

Speaker: Axel Grawingholt (Belgium)

12:15 **The European quality assurance scheme**

Speaker: Robert E. Mansel (United Kingdom)

12:25 **Implementation of ECIBC by breast cancer services: Practical aspects**


Speaker: Luciana Neamtiu (Italy)

The European Commission Initiative on Breast Cancer (ECIBC) Quality Assurance (QA) Scheme defines a common set of quality and safety requirements for breast cancer services in Europe, as well as training requirements for professionals involved in breast cancer care. It focuses on aspects that are relevant to citizens and patients, and covers all the relevant care processes from screening until the end-of-life care. The QA Scheme adheres to evidence-based guidelines. This has been linked with achieving better health outcomes.

The QA Scheme aims to support quality breast cancer care across Europe and decrease inequalities in care. Implementation of the scheme is voluntary. The initiative has been developed in a flexible way, adaptable to national contexts.

Additional resources are available to support implementation of the ECIBC. These are all free to access from the ECIBC website and can be independently used to monitor and improve the quality of breast cancer care.

12:35 **Discussion**



Closing Plenary Session: Keynote Lecture and Manifesto Session

13:00 - 14:30

Picasso

Chair: Nadia Harbeck (Germany)

Co-Chair: Tanja Spanic (Slovenia)

Chair: Javier Cortés (Spain)

13:00 **Endocrine resistance and how it affects management in your daily practice**

Keynote Speaker: Nick Turner (United Kingdom)

13:30 **Manifesto session: Bridging the Gap Between Evidence Based Medicine and Reality – Why it is Needed - further info see separate session**

Manifesto Session: Manifesto: Why don't all European breast cancer patients get the most appropriate care?

13:30 - 14:30

Picasso

Medical Oncologist

Chair: Fátima Cardoso (Portugal)

Radiation Oncologist

Chair: Philip Poortmans (Belgium)

Surgeon

Panel: Fiona MacNeill (United Kingdom)

Pathologist

Panel: Frédérique Penault-Llorca (France)

Medical Oncologist

Panel: Alexandru Eniu (Romania)

Health Technology Assessor


Panel: Francois Maignen (United Kingdom)

Imaging

Panel: Francesco Sardanelli (Italy)

Patient Advocate

Panel: Elizabeth Bergsten-Nordstrom (Sweden)



President European Breast Cancer Council (EBCCouncil)

Panel: Emiel J. T. Rutgers (Netherlands)

Scientific writer

John Bean (Belgium)